<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
    "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title>gnpx-10q_20180331.htm</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
UNITED STATES</p>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
SECURITIES AND EXCHANGE COMMISSION</p>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Washington, D.C. 20549<font style=
"font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
FORM 10-Q<font style="font-weight:normal;">&nbsp;</font></p>
<p style=
"Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
(Mark One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
☒</font></p>
</td>
<td valign="top">
<p style=
"Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">
<font style="font-weight:bold;">QUARTERLY REPORT UNDER SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
For the quarterly period ended&nbsp;March 31, 2018</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:MS Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:MS Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
☐</font></p>
</td>
<td valign="top">
<p style=
"Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">
<font style="font-weight:bold;">TRANSITION REPORT UNDER SECTION 13
OR 15(d) OF THE EXCHANGE ACT</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
For the transition period from __________________ to
______________</p>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Commission file number: 001-38244</p>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">GENPREX, INC.</font></p>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">(Exact name of registrant
as specified in its charter)</font></p>
<p style=
"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Delaware</font></p>
</td>
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">90 - 0772347</font></p>
</td>
</tr>
<tr style="height:1pt;">
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(State or other jurisdiction of</p>
</td>
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(I.R.S. Employer</p>
</td>
</tr>
<tr style="height:1pt;">
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
incorporation or organization)</p>
</td>
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Identification Number)</p>
</td>
</tr>
<tr style="height:1pt;">
<td valign="top" style="width:50%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:50%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr style="height:1pt;">
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">1701 Trinity Street, Suite
3.322, Austin, TX</font></p>
</td>
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">78705</font></p>
</td>
</tr>
<tr style="height:1pt;">
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(Address of principal executive offices)</p>
</td>
<td valign="top" style="width:50%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(Zip Code)</p>
</td>
</tr>
</table>
</div>
<p style=
"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">
&nbsp;</p>
<p style=
"text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="Background-color:#FFFFFF;">Registrant’s telephone
number, including area code:</font> <font style=
"font-weight:bold;text-decoration:underline;Background-color:#FFFFFF;">
(512) 370-4081</font></p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.&nbsp; Yes&nbsp;<font style=
"font-family:MS Gothic;">☒</font>&nbsp;&nbsp;&nbsp;No&nbsp;<font style="font-family:MS Gothic;">☐</font></p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or
for such shorter period that the registrant was required to submit
and post such files). Yes&nbsp;<font style=
"font-family:MS Gothic;">☒</font>&nbsp;&nbsp;&nbsp;No&nbsp;<font style="font-family:MS Gothic;">☐</font></p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See
definition of “large accelerated filer,” accelerated filer” 
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act:&nbsp;</p>
<p style=
"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Large accelerated filer</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">
<font style=
"font-size:10pt;font-family:'Times New Roman'">☐</font></p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accelerated filer</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">
<font style=
"font-size:10pt;font-family:'Times New Roman'">☐</font></p>
</td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Non-accelerated filer</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">
<font style=
"font-size:10pt;font-family:'Times New Roman'">☐</font></p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(Do not check if a smaller reporting company)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Smaller reporting company</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:MS Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
☒</p>
</td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Emerging growth company</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:MS Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
☒</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
</tr>
</table>
</div>
<p style=
"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">
&nbsp;</p>
<p style=
"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.&nbsp;<font style="font-family:Segoe UI Symbol;">☒</font></p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).
Yes&nbsp;<font style="font-family:Segoe UI Symbol;">☐</font>&nbsp;
No&nbsp;<font style=
"font-family:Segoe UI Symbol;">☒</font>&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style=
"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As of May 15, 2018, the registrant had 13,896,926 shares of voting
common stock, par value $0.001 per share, outstanding.</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0.02%;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU2" id=
"_AEIOULastRenderedPageBreakAEIOU2"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENPREX,
INC.</font></p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="TABLEOFCONTENTS" id="TABLEOFCONTENTS"></a>TABLE OF
CONTENTS</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style=
"width:8.08%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style=
"width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style=
"width:82.84%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style=
"width:1%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style=
"width:7%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">
Page No.</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="top" style=
"width:7%; border-top:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
PART I</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#PART_I_FINANCIAL_INFORMATION"><font style=
"text-decoration:underline;">FINANCIAL INFORMATION</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
3</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ITEM 1.</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#ITEM_1_FINANCIAL_STATEMENTS"><font style=
"text-decoration:underline;">FINANCIAL STATEMENTS</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
3</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#BALANCE_SHEETS"><font style=
"text-decoration:underline;">Condensed Balance Sheets as of March
31, 2018 (unaudited) and December 31, 2017</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
3</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#STATEMENTS_OPERATIONS"><font style=
"text-decoration:underline;">Condensed Statements of Operations for
the Three Months Ended March 31, 2018 and 2017
(unaudited)</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
4</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#CashFlows"><font style=
"text-decoration:underline;">Condensed Statements of Cash Flows for
the Three Months Ended March 31, 2018 and 2017
(unaudited)</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
5</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#NOTES"><font style="text-decoration:underline;">Notes to
Condensed Financial Statements (unaudited)</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
6</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ITEM 2.</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:-13.7pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style=
"text-decoration:underline;">MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND<br />
RESULTS OF OPERATIONS</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
14</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ITEM 4.</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#Item4.Controls"><font style=
"text-decoration:underline;">CONTROLS AND PROCEDURES</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
18</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
PART II</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#PART_II_OR_INFORMATION"><font style=
"text-decoration:underline;">OTHER INFORMATION</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
19</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ITEM 1.</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#Item1.Legal"><font style=
"text-decoration:underline;">LEGAL PROCEEDINGS</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
19</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ITEM 1A.</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#Item1A.Risk"><font style=
"text-decoration:underline;">RISK FACTORS</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
19</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ITEM 2.</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#Item2.Unregistered"><font style=
"text-decoration:underline;">UNREGISTERED SALES OF EQUITY
SECURITIES AND USE OF PROCEEDS</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
49</p>
</td>
</tr>
<tr>
<td valign="top" style="width:8.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ITEM 6.</p>
</td>
<td valign="top" style="width:1.08%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:82.84%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#Item6.Exhibits"><font style=
"text-decoration:underline;">EXHIBITS</font></a></p>
</td>
<td valign="top" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:7%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
50</p>
</td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:92%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="#SIGNATURES"><font style=
"text-decoration:underline;">SIGNATURES</font></a></p>
</td>
<td colspan="2" valign="bottom" style="width:8%;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
52</p>
</td>
</tr>
</table>
</div>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU3" id=
"_AEIOULastRenderedPageBreakAEIOU3"></a><a name=
"PART_I_FINANCIAL_INFORMATION" id=
"PART_I_FINANCIAL_INFORMATION"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I_FINANCIAL_INFORMATION"
id="PART_I_FINANCIAL_INFORMATION"></a>PART I -
FINANCI</font><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AL
INFORMATION</font></p>
<p style=
"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="ITEM_1_FINANCIAL_STATEMENTS" id=
"ITEM_1_FINANCIAL_STATEMENTS"></a><a name=
"ITEM_1_FINANCIAL_STATEMENTS" id=
"ITEM_1_FINANCIAL_STATEMENTS"></a>Item 1. Financial Statements.</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Genprex, Inc.</p>
<p style=
"text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="BALANCE_SHEETS" id="BALANCE_SHEETS"></a>Condensed <a name=
"BALANCE_SHEETS" id="BALANCE_SHEETS"></a>Balance Sheets
(unaudited)</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
March 31,</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
December 31,</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2018</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2017</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Assets</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Current assets:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Cash</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
24,485</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
161,251</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accounts receivable</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
838</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
8,844</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Prepaid expenses and other</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
33,074</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
23,479</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Total current assets</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
58,397</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
193,574</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Property and equipment, net</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
8,326</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
7,804</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Other assets:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Deferred offering costs</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,012,106</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
759,591</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Intellectual property, net</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
307,552</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
298,569</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Total other assets</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,319,658</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,058,160</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Total assets</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,386,381</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,259,538</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Liabilities and Stockholders’ Equity</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Current liabilities:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accounts payable and accrued expenses</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,149,008</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
629,074</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Notes payable - related parties</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
279,288</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
201,890</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Total current liabilities</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,428,296</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
830,964</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Investment unit</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Commitments and contingencies</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Stockholders’ equity:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Common stock $0.001 par value: 200,000,000 shares authorized;
11,755,004</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;&nbsp; and 11,721,584 shares issued and outstanding,
respectively</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
11,755</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
11,721</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Additional paid-in capital</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
18,092,682</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
17,869,205</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accumulated deficit</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(18,146,352</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(17,452,352</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Total stockholders’ equity (deficit)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(41,915</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
428,574</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Total liabilities and stockholders’ equity</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,386,381</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,259,538</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
</table>
</div>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
See accompanying notes to the unaudited condensed financial
statements</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
3</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU4" id=
"_AEIOULastRenderedPageBreakAEIOU4"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Genprex,
Inc.</font></p>
<p style=
"text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="STATEMENTS_OPERATIONS" id=
"STATEMENTS_OPERATIONS"></a>Condensed <a name=
"STATEMENTS_OPERATIONS" id="STATEMENTS_OPERATIONS"></a>Statements
of Operations (unaudited)</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Three Months Ended</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
March 31,</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2018</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2017</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Revenues</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Cost and expenses:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Depreciation</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
947</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
597</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Research and development</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
51,621</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
68,364</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
General and administrative</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
634,063</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
682,342</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Total costs and expenses</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
686,631</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
751,303</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Operating loss</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(686,631</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(751,303</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Interest income</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
28</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Interest expense</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(7,398</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Net loss</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(694,001</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(751,303</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Net loss per share—basic and diluted</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(0.06</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(0.07</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Weighted average number of common shares— basic and diluted</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
11,738,294</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
11,380,881</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
</table>
</div>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
See accompanying notes to the unaudited condensed financial
statements.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
4</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU5" id=
"_AEIOULastRenderedPageBreakAEIOU5"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Genprex,
Inc.</font></p>
<p style=
"text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="CashFlows" id="CashFlows"></a><a name="CashFlows" id=
"CashFlows"></a>Condensed Statements of Cash Flows (unaudited)</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Three Months Ended</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
March 31,</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2018</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2017</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Cash flows from operating activities:</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net loss</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(694,001</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(751,303</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Adjustments to reconcile net loss to net cash used in operating
activities:</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Depreciation</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
947</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
597</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Share based compensation</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
223,512</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
233,447</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Changes in operating assets and liabilities:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accounts receivable</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
8,006</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
8,182</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Prepaid expenses and other</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(9,595</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
4,286</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Deferred offering costs</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(252,515</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(28,368</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accounts payable and accrued expenses</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
519,934</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(116,150</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash used in operating activities</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(203,712</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(649,309</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Cash flows from investing activities:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Additions to property and equipment</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(1,469</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(2,751</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Additions to intellectual property</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(8,983</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(20,227</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash used in investing activities</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(10,452</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(22,978</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Cash flows from financing activities:</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Proceeds from notes payable - related parties</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
77,398</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash provided by financing activities</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
77,398</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net (decrease) in cash</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(136,766</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(672,287</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Cash, beginning of period</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
161,251</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1,602,295</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Cash, end of period</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
24,485</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
930,008</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
</table>
</div>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
See accompanying notes to the unaudited condensed financial
statements.</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
5</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU6" id=
"_AEIOULastRenderedPageBreakAEIOU6"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENPREX,
INC.</font></p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_bookmark5" id="_bookmark5"></a><a name="NOTES" id=
"NOTES"></a>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 1—Description of
Business and Basis of Presentation</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Genprex, Inc. ("we" or "the Company"), is <font style=
"Background-color:#FFFFFF;">a clinical stage gene therapy company
developing a new approach to treating cancer, based upon a novel
proprietary technology platform, including our initial product
candidate, Oncoprex immunogene therapy for non-small cell lung
cancer (NSCLC). Our platform technologies are designed to
administer cancer fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then
administered intravenously and taken up by tumor cells where they
express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance.</font>&nbsp;&nbsp;</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We are subject to all the risks inherent in a start-up company in
the biopharmaceutical industry. The biopharmaceutical industry is
subject to rapid and technological change. We have numerous
competitors, including major pharmaceutical and chemical companies,
specialized biotechnology firms, universities and other research
institutions. These competitors may succeed in developing
technologies and products that are more effective than any that are
being developed by us or that would render our technology and
products obsolete and noncompetitive. Many of these competitors
have substantially greater financial and technical resources than
us. In addition, many of our competitors have significantly greater
experience than us in pre-clinical testing and human clinical
trials of new or improved pharmaceutical products and in obtaining
FDA and other regulatory approvals on products for use in health
care.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Capital Requirements,
Liquidity and Going Concern Considerations</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our condensed financial statements are prepared using the generally
accepted accounting principles applicable to a going concern, which
contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, as shown in
the accompanying condensed financial statements, we have sustained
substantial losses from operations since inception and have no
current source of revenue. In addition, we have used, rather than
provided, cash in our operations. We expect to continue to incur
significant expenditures to further clinical trials for the
commercial development of our patents.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Management recognizes that we must obtain additional resources to
successfully commercialize our intellectual property.&nbsp;&nbsp;To
date, we have received funding in the form of equity and debt, and
we plan to seek additional funding in the future. However, no
assurances can be given that we will be successful in raising
additional capital.&nbsp;&nbsp;If we are not able to timely and
successfully raise additional capital, the timing of our clinical
trials, financial condition and results of operations will continue
to be materially affected. These condensed financial statements do
not include any adjustments relating to the recoverability and
classification of recorded asset amounts and classification of
liabilities.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 2—Summary of
Significant Accounting Policies</font></p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;color:#auto;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The Company’s condensed financial statements have been prepared in
accordance with U.S. generally accepted accounting principles (
“GAAP”). <font style="color:#212121;">Accordingly, they do not
include all the information and footnotes required by generally
accepted accounting principles for complete financial statements.
In our opinion the unaudited condensed financial statements include
all adjustments (consisting of normal recurring accruals) necessary
to make the unaudited condensed financial statements not
misleading. Operating results for the three months ended March 31,
2018 are not necessarily indicative of the final results that may
be expected for the year ending December 31, 2018. For more
complete financial information, these unaudited condensed financial
statements should be read in conjunction with the audited financial
statements for the year ended December 31, 2017 filed with the
SEC.</font> A summary of our significant accounting policies
consistently applied in the preparation of the accompanying
condensed financial statements follows.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Capital Stock</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In connection with the Company’s completed IPO (see Subsequent
Events note) in April 2018, all of the Company’s Preferred Stock
and Non-Voting Common Stock were converted into shares of the
Company’s Common Stock. The Company’s Common Stock was then
forward-split at a ratio of 6.6841954-to-1. Furthermore, prior to
the closing of the IPO, the Company’s Certificate of Incorporation
was amended and restated to provide the Company with the authority
to issue up to 210,000,000 shares of stock consisting of
200,000,000 shares of Common Stock at a par value of $0.001 per
share and 10,000,000 shares of Preferred Stock at a par value of
$0.001 per share.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
6</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU7" id=
"_AEIOULastRenderedPageBreakAEIOU7"></a><font style=
"text-decoration:underline;">Use of Estimates</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The preparation of our condensed financial statements in conformity
with GAAP requires us to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the condensed
financial statements and the reported amounts of expenses during
the reporting period. Actual results could differ from those
estimates.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Cash</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We consider all highly liquid short-term investments with an
initial maturity of three months or less to be cash
equivalents.&nbsp;&nbsp;Any amounts of cash in financial
institutions which exceed FDIC insured limits expose us to cash
concentration risk. We have no cash equivalents, and had $0 in
excess of FDIC insured limits of $250,000 at March 31, 2018 and
December 31, 2017 respectively.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Fair Value of Financial
Instruments</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The carrying amounts reported in the balance sheet for cash,
accounts receivable, accounts payable and accrued expenses
approximate fair value because of the immediate or short-term
maturity of these financial instruments.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
ASC 820, Fair Value Measurements and Disclosures, defines fair
value, provides a consistent framework for measuring fair value
under GAAP and expands fair value financial statement disclosure
requirements. ASC 820’s valuation techniques are based on
observable and unobservable inputs. Observable inputs reflect
readily obtainable data from independent sources, while
unobservable inputs reflect our market assumptions. ASC 820
classifies these inputs into the following hierarchy:</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Level 1:<font style="font-size:1pt;">&nbsp;</font>Quoted prices for
identical instruments in active markets</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Level 2: Quoted prices for similar instruments in active markets;
quoted prices for identical or similar instruments in markets that
are not active; and model-derived valuations whose inputs are
observable or whose significant value drivers are observable</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Level 3:<font style="font-size:1pt;">&nbsp;</font>Instruments with
primarily unobservable value drivers.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Property and
Equipment</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Furniture and equipment are stated at cost. Depreciation is
calculated using the straight line method over the estimated useful
lives of the assets, which range from three to five years. Routine
maintenance and repairs are charged to expense as incurred and
major renovations or improvements are capitalized.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Research and Development
Materials Costs</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Research and development expenditures are comprised of costs
incurred to conduct research and development activities. These
include payments to collaborative research partners, including
wages and associated employee benefits, facilities and overhead
costs. These expenditures relate to Phase I and II clinical trials
and are expensed as incurred. Purchased materials to be used in
future research are capitalized and included in prepaid
expenses.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Awards</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In 2010, we were awarded $4.5 million from the State of Texas
Emerging Technology Fund (“TETF”). The award was received in two
tranches of $2.25 million during 2010 and 2011. The award proceeds
were used for the development and future commercialization of our
nanomolecular therapy product for the treatment of cancer. In
consideration for the award, we provided the TETF with an 
“Investment Unit”, consisting of (i) a Promissory Note (“Note”) and
(ii) a right to purchase our equity shares (“Warrant”). The funds
received for this award were assigned to the Investment Unit, and
classified separately from equity as “mezzanine” in the balance
sheet.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In 2010, we also were awarded approximately $244,500 from the U.S.
Treasury Department for our QTDP Program Nanoparticle Therapy for
Lung Cancer. The award was received during 2011 for our historical
activities, and required no prospective expenditures. We accounted
for these funds received as revenue at that time.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
7</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU8" id=
"_AEIOULastRenderedPageBreakAEIOU8"></a><font style=
"text-decoration:underline;">Intellectual</font> <font style=
"text-decoration:underline;">Property</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Intellectual property consists of external legal and related costs
associated with patents and other proprietary technology acquired,
licensed, or maintained by us that we believe contribute to a
probable economic benefit toward such patents and activities. These
legal costs incurred in connection with the patent applications and
patent maintenance are capitalized. Intellectual property is stated
at cost, to be amortized on a straight-line basis over the
estimated useful lives of the assets.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Accounting for Stock-Based
Compensation</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We use the fair value-based method of accounting for stock-based
compensation for options granted to employees, independent
consultants and contractors. We measure options granted at fair
value determined as of the grant date, and recognize the expense
over the periods in which the related services are rendered based
on the terms and conditions of the award. Generally, where the
award only has a service condition, the requisite service period is
the same as the vesting period.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Financial
Instruments</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We have elected the Fair Value Option to account for the Investment
Unit at fair value as a combined hybrid financial instrument
containing a Warrant and a Note (see Investment Unit
Note).&nbsp;&nbsp;Prior to its exercise, the Warrant component was
not classified within equity, as the exercise price of the warrants
was affected by the market price of our stock in a future
qualifying financing transaction and was not considered to be
indexed to our own stock. The Note is not classified within
liabilities, as our management can determine the timing of the
repayment obligation, if any. As a result, the Warrant and Note
that comprised the Investment Unit were aggregated and classified
within the mezzanine section of the balance sheet.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Due to the contingent terms of the financial instruments, changes
in the fair value of the Investment Unit were calculated and
realized in earnings.&nbsp;&nbsp;There were no changes in the fair
value of the Investment Unit at March 31, 2018.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Long-Lived
Assets</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We review long-lived assets and certain identifiable intangibles
held and used for possible impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not
be recoverable. In evaluating the fair value and future benefits of
its intangible assets, management performs an analysis of the
anticipated undiscounted future net cash flow of the individual
assets over the remaining amortization period. We recognize an
impairment loss if the carrying value of the asset exceeds the
expected future cash flows. During the three months ended March 31,
2018 and the year ended December 31, 2017, there were no deemed
impairments of our long-lived assets.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Recent Accounting
Developments</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accounting pronouncements issued but not effective until after
March 31, 2018 are not expected to have a significant effect on our
financial condition, results of operations, or cash flows.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 3—Intellectual
Property</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We have exclusive license agreements on thirty (30) issued and two
(2) pending patents for technologies developed by researchers at
the National Cancer Institute, The University of Texas MD Anderson
Cancer Center, and The University of Texas Southwestern Medical
Center.&nbsp;&nbsp;These patents comprise various therapeutic,
diagnostic, technical and processing claims. These license rights
will be amortized on a straight-line basis over the estimated
period of useful lives of the underlying patents or the license
agreements.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 4—Investment
Unit</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The Texas Emerging Technology Fund (“TETF”) was created as an
incentive for economic development to the Texas economy by
providing financial support that leverages private investment for
the creation of high-quality technology jobs in Texas. The award
received required us to comply with certain performance conditions
to ensure the monies the Company received were used for development
activities in the state of Texas, and that we maintained our
corporate nexus in Texas. Further, in connection with the award,
the Company issued an Investment Unit to the TETF. As further
described below, the Investment Unit consists of a Promissory Note
and a Right to Purchase.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
8</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU9" id=
"_AEIOULastRenderedPageBreakAEIOU9"></a><font style=
"text-decoration:underline;">Promissory Note</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The Promissory Note is an obligation to repay the $4.5 million
principal amount, with interest accrued at 8% per annum, but only
if an event of default occurs prior to August 13, 2020. If no event
of default occurs prior to August 13, 2020, the Promissory Note and
all related interest will be cancelled.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Consistent with the stated objectives of the TETF, an event of
default that would trigger the repayment obligation under the
Promissory Note is our failure to maintain our principal place of
business or our principal executive offices headquartered in the
State of Texas (referred to as the “Residency Requirement”) until
August 13, 2020.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Warrant</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The Warrant is an obligation to issue (a Right to purchase by the
TETF) shares of the same class of stock to be issued in a “First
Qualifying Financing Transaction,” at 80% of the per share
transaction value (effectively a 20% discount). Alternatively, the
TETF could exercise its right to purchase at any time prior to the
occurrence of a First Qualifying Financial Transaction for $0.001
per share.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The Warrant included a provision that required changes in the
strike price, driven by the pricing of the “First Qualifying
Financing Transaction.” As a result, the Warrants embedded in the
Investment Unit were accounted for as a derivative financial
instrument and classified outside from equity under ASC 815-40-15
as the settlement adjustment from the future transaction did not
permit for the strike price to be considered fixed.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
On March 12, 2014, the TETF exercised its Right to Purchase for
$0.001 per share, and we issued to the TETF an aggregate of 184,797
shares of our Series B preferred stock. These shares were
subsequently forward-split and converted to 1,235,219 shares of
Common Stock in connection with our IPO.&nbsp;&nbsp;</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Accounting for the
Investment Unit</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We accounted for the Investment Unit as a hybrid financial
instrument under FASB Statement 155, and measured the Investment
Unit at the amount of proceeds received from the TETF award. The
First Qualifying Financial Transaction occurred during December
2013, resulting in an adjustment to the fair value of the
Investment Unit in the amount of approximately $2.5 million. The
TETF exercised the Warrant for $0.001 per share. We received notice
of purchase from the TETF during March 2014, and issued 184,797
shares of series B Preferred Stock, which has since been converted
to 1,235,219 shares of Common Stock upon completion of the Company’
s IPO. Upon exercise by the TETF of the Warrant, the remaining
component within the Investment Unit was the Promissory Note. The
Investment Unit was valued at zero, because our obligation to repay
the Promissory Note arises from an event of default (a failure to
maintain the Texas Residency Requirement), which is an event which
rests entirely within our control.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 5—Equity</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Stock Issuances</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
During the quarter ended March 31, 2018, we issued (i) 33,420
shares of Common Stock, taking into account the forward-split ratio
from the Company’s IPO, for service provided to us, valued at
$176,650.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
During the year ended December 31, 2017, we issued (i) 207,206
shares of Common Stock, taking into account the forward-split ratio
from the Company’s IPO, for service provided to us, valued at
$1,095,230 and we issued (ii) 22,473 shares of Series G Preferred
Stock, which has since been converted to Common Stock and
forward-split representing 150,211 shares of Common Stock, for cash
of $793,971.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Preferred Stock</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In connection with the Company’s IPO, all Preferred Stock included
in Series A through Series G, totaling 1,394,953 shares at December
31, 2017, were converted to 9,324,177 shares of Common Stock as a
result of the forward-split (See Capital Stock Note). Upon the
completion of the IPO, the Company is authorized to issue
10,000,000 shares of Preferred Stock at a par value of $0.001 per
share, none of which is outstanding as of March 31, 2018.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
9</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU10" id=
"_AEIOULastRenderedPageBreakAEIOU10"></a><font style=
"text-decoration:underline;">Common Stock</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Upon the completion of the IPO, all of the Company’s Non-Voting
Common Stock automatically converted to into Voting Common Stock on
a one-to-one basis. Immediately following the completion of the
IPO, the Company is authorized to issue 200,000,000 shares of
Common Stock at a par value of $0.001 per share, which includes
200,000,000 shares of Voting Common Stock at a par value of
$0.001.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Common Stock Purchase
Warrants</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;color:#auto;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Common Stock purchase warrant activity for the period and year
ended March 31, 2018 and December 31, 2017 respectively are as
follows:</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Number of</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Warrants</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Weighted Avg.</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Exercise Price</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Outstanding at January 1, 2017</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
748,060</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
5.17</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Issued</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Cancelled or expired</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Exercised</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Outstanding at December 31, 2017</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
748,060</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
5.17</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Issued</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Cancelled or expired</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Exercised</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Outstanding at March 31, 2018</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
748,060</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
5.17</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">
&nbsp;</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Stock Options</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We have outstanding stock options to purchase 2,628,749 shares of
Common Stock, taking into account the forward-split ratio from the
Company’s IPO, that have been granted to various employees, vendors
and independent contractors. These options vest over periods
ranging from twelve (12) to forty-eight (48) months, are
exercisable for a period of ten years, and enable the holders to
purchase shares of our Common Stock at exercise prices ranging from
$0.001 - $5.286. The per-share fair values of these options range
from $0.001 to $2.68, based on Black-Scholes-Merton pricing models
with the following assumptions.&nbsp;&nbsp;The weighted average
remaining contractual term for the outstanding options at March 31,
2018 and December 31, 2017 is 7.01 and 7.26 years,
respectively.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
There was no stock option activity for the three months ended March
31, 2018. Stock option activity for the quarter and year ended
March 31, 2018 and December 31, 2017, respectively, is as
follows:</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Number of</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Shares</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Weighted Avg.</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Exercise Price</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Outstanding at January 1, 2017</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
2,628,749</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1.31</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Options granted</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Options exercised</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Options expired</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Outstanding at December 31, 2017</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
2,628,749</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1.31</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Options granted</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Options exercised</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Options expired</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="middle" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Outstanding at March 31, 2018</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
2,628,749</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
1.31</p>
</td>
<td valign="middle" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
10</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU11" id=
"_AEIOULastRenderedPageBreakAEIOU11"></a><font style=
"text-decoration:underline;">Note 6—Related Party
Transaction</font><font style=
"text-decoration:underline;">s</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Domecq Sebastian,
LLC</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Domecq-Sebastian LLC (“Domecq”) is an entity affiliated with David
Nance, a former director and officer who is now deceased. During
December 2017, we entered into a promissory note with Domecq for a
total amount of $200,000 that carries a 15% interest rate and is
due and payable on or before March 31, 2018. The note carries a 18%
default interest on amounts paid after the maturity date. This note
was subsequently repaid in full in April 2018.&nbsp;&nbsp;</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Introgen Research
Institute</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Introgen Research Institute (“IRI”) is a Texas-based technology
company, currently affiliated with Rodney Varner, our CEO. In April
2009, prior to Mr. Varner becoming an officer and director of our
Company in August 2012, we entered into an Assignment and
Collaboration Agreement with IRI, providing us with the exclusive
right to commercialize a portfolio of intellectual property. This
agreement was amended in 2011 to include additional sublicensing of
additional intellectual property made available to IRI from the
University of Texas MD Anderson Cancer Center (“UTMDACC”).</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Rodney Varner</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Rodney Varner is the Company’s Chief Executive Officer. On March
28, 2018, we entered into a promissory note with Rodney Varner,
Trustee, for a total amount of $45,000 that carries a 0% interest
rate and is due and payable on or the earlier of (i) five days
after funding of the Company’s initial public offering, or (ii)
April 30, 2018, the maturity date. If paid after the maturity date,
the note carries a 10% interest rate. This note was paid in full
prior to the maturity date in April 2018.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Viet Ly</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Viet Ly manages several investment funds that have provided the
Company with investment funds since 2013. On March 9, 2018, we
entered into a promissory note with Viet Ly for a total amount of
$25,000 that carries a 0% interest rate and is due and payable on
or before June 9, 2018, the maturity date. If paid after the
maturity date, the note carries a 10% interest rate. This note was
paid in full prior to the maturity date in April 2018.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 7—Commitments and
Contingencies</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Commitments</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We have entered into a clinical trial agreement with the University
of Texas MD Anderson Cancer Center to administer a Phase I/II
clinical trial, combining FUS1-nanoparticles and Erlotinib in Stage
IV lung cancer patients. The trial is expected to run through early
2019 with a projected total cost of approximately $2 million.
Payments are due and payable when invoiced throughout the clinical
trial period. The agreement may be terminated at any time.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In 2009, we agreed to assume certain contractual and other
obligations of IRI in consideration for the sublicense rights,
expertise, and assistance associated with the assignment of certain
technologies and intellectual property. We also agreed to pay
royalties of one percent (1%) on sales of resulting Licensed
Products, for a period of 21 years following the termination of the
last of the MD Anderson License Agreement and Sublicense Agreement,
to IRI and we assumed patent prosecution costs and an annual
minimum royalty of $20,000 payable to the National Institutes of
Health (“NIH”).</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our $191,393 payment obligation to the National Institutes of
Health (“NIH”) represented a current obligation, of which $15,393
of 2016 patent prosecution costs were paid in the fourth quarter of
2016 and $176,000 was included in Accounts Payable at December 31,
2016 (consisting of accrued annual royalties of $140,000 and patent
costs of $36,000). During the first quarter of 2017, we modified
the terms of our accrued royalty obligation to NIH. Under the
modified agreement, NIH agreed to extinguish $120,000 of the
accrued royalties payable to them in consideration for payment by
us of (i) accrued patent costs of $36,000, (ii) a royalty payment
of $20,000, and (iii) a contingent payment of $240,000, increasing
at $20,000 per year starting in 2018, to be paid upon our receipt
of FDA approval. The payments for the patent costs of $36,000 and
royalties of $20,000 were paid during the second quarter of
2017.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As a result of our modified agreement with the NIH, we have
recognized the exchange of the $120,000 fixed obligation for the
$240,000 contingent obligation as a $120,000 reduction to
intellectual property expense (classified within General and
Administrative Expense) during the first quarter of 2017. The
$240,000 contingent obligation (and related expense) will be
recognized when we obtain regulatory approval (the event that
triggers the payment obligation).</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
11</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU12" id=
"_AEIOULastRenderedPageBreakAEIOU12"></a><font style=
"text-decoration:underline;">Contingencies</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
From time to time we may become subject to threatened and/or
asserted claims arising in the ordinary course of our business.
Management is not aware of any matters, either individually or in
the aggregate, that are reasonably likely to have a material impact
on our Company’s financial condition, results of operations or
liquidity.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
During October 2017, we received an informal demand from a former
financial advisor, claiming that it is entitled to a warrant to
purchase shares of common stock equal to three (3) percent of our
outstanding shares at December 1, 2015. We believe this asserted
claim lacks merit, and we intend to defend the claim
vigorously.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 8—Income
Taxes</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The provision for income taxes differs from the amount computed by
applying the statutory federal income tax rate to income before
provision for income taxes. The sources and tax effects of the
differences are as follows:</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Income tax provisions at the federal statutory rate</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
34</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
%</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Effect of operating losses</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
-34</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
%</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
0</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
%</p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
At December 31, 2017, we have a net operating loss carryforward of
approximately $8.0 million for Federal and state purposes. This
loss will be available to offset future taxable income. If not
used, this carryforward will begin to expire in 2029. The deferred
tax asset relating to the operating loss carryforward has been
fully reserved at March 31, 2018 and December 31, 2017. The
principal differences between the operating loss for income tax
purposes and reporting purposes are shares issued for services and
share-based compensation and a temporary difference in depreciation
expense.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Note 9—Subsequent
Events</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Initial Public
Offering</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
On April 3, 2018, the Company completed its IPO, whereby the
Company sold an aggregate of 1,280,000 shares of its common stock,
at $5.00 per share, resulting in estimated net proceeds of
$5,025,000 after underwriting discounts, commissions and estimated
offering expenses of $895,000. Additionally, the underwriters have
been issued warrants to purchase common stock equal to 3% of the
securities sold in the IPO, or 38,400 shares of Common Stock.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">2018 Equity Incentive
Plan</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The <font style="color:#353535;">Company’s board of directors and
stockholders has approved and adopted the Company’s 2018 Equity
Incentive Plan (“2018 Plan”), which became effective on the
completion of the IPO on April 3, 2018. The 2018 Plan provides for
the grant of incentive stock options (“ISOs”), nonstatutory stock
options, stock appreciation rights, restricted stock awards,
restricted stock unit awards, performance-based stock awards, other
forms of equity compensation and performance cash awards. ISOs may
be granted only to employees. All other awards may be granted to
employees, including officers, and to the Company’s non-employee
directors and consultants, and affiliates.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#353535;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
A total of 4,160,000 shares of Common Stock are available under the
2018 Plan, which includes 554,963 shares of Common Stock reserved
for issuance under our 2009 Equity Incentive Plan that were added
to 2018 Plan. No further grants will be made under the 2009 Plan
and any shares subject to outstanding stock options under the 2009
Plan that would otherwise be returned to the 2009 Plan will instead
be added to the shares initially reserved under the 2018 Plan.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#353535;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, the number of shares of common stock reserved for
issuance under the 2018 Plan will automatically increase on January
1 of each year, beginning on January 1, 2019 by 5% of the total
number of shares of the Company’s Common Stock outstanding on
December 31 of the preceding calendar year, or a lesser number of
shares determined by the administrator of the 2018 Plan.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">2018 Employee Stock
Purchase Plan</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The <font style="color:#353535;">Company’s board of directors and
stockholders has approved and adopted the Company’s 2018 Employee
Stock Purchase Plan (“ESPP”), which became effective on the
completion of the IPO on April 3, 2018. The ESPP authorizes the
issuance of 208,500 shares of the Company’s common stock pursuant
to purchase rights granted to our eligible employees. The number of
shares of common stock reserved for issuance will automatically
increase on January 1 of each calendar year, from January 1, 2019
by the lesser of 2% of the total number of shares of our common
stock outstanding on December 31 of the preceding calendar year or
a number determined by the administrator of the ESPP.</font></p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
12</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU13" id=
"_AEIOULastRenderedPageBreakAEIOU13"></a><font style=
"text-decoration:underline;">Le</font><font style=
"text-decoration:underline;">ases</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
On April 16, 2018, the Company executed a service agreement with
CIC Innovation Communities, LLC, to establish and lease offices at
the Cambridge Innovation Center at 1 Broadway, Floor 14, Cambridge,
MA 02142. The Company does not have a long-term agreement in place
to occupy this location, but rather occupies on a month-to-month
basis.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
On April 16, 2018, the Company also executed a space utilization
agreement with the Board of Regents of the University of Texas
System to establish and lease offices at the Dell Medical School
located 1701 Trinity Street, Suite 3.322, Austin, Texas 78705. The
Company pays $4,000 per month to occupy this location and the lease
is effective until October 31, 2018.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Private
Investment</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
On May 9, 2018, the Company completed a private placement, whereby
the Company sold to investors an&nbsp;aggregate of 828,500 shares
of its common stock at $12.07 per share&nbsp;and warrants to
purchase up to 621,376 shares of the Company’s common stock with an
initial exercise price equal to $15.62 per share. The per share
price and warrant exercise price will automatically be adjusted
lower, if applicable, based on the volume weighted average daily
prices on the three days after the registration statement is
declared effective and the Company's shareholders approve the
transaction. In no event will&nbsp;the purchase price or warrant
exercise price be less than $4.25 per share.&nbsp;The Company
received net proceeds of $9,250,000 after commissions and expenses.
Maxim Group LLC served as the placement agent.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style="text-decoration:underline;">Warrants</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The Company plans to issue warrants to purchase shares of common
stock at no less than $5.00 per share to key service providers and
consultants in conjunction with past and future services provided
to the Company. The Company plans to issue warrants to purchase (i)
425,000 shares of common stock to Cancer Revolution, LLC, (ii)
225,000 shares of common stock to Cancer Biotech, LLC, (iii)
144,352 shares of common stock to Inception Capital Management,
LLC, and (iv) 50,000 shares of common stock to World Wide Holdings,
LLC.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
13</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="Item2.Managements" id="Item2.Managements"></a><a name=
"_AEIOULastRenderedPageBreakAEIOU14" id=
"_AEIOULastRenderedPageBreakAEIOU14"></a><a name=
"ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F" id=
"ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"
id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>tem 2. Management’
s Discussion and Analysis of</font> <font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Financial Condition and Results of Operations</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
The following discussion and analysis of our financial condition
and results of operations should be read in conjunction with our
unaudited condensed financial statements and related notes included
in this Quarterly Report on Form 10-Q and the audited financial
statements and notes thereto as of and for the year ended December
31, 2017 and the related Management’s Discussion and Analysis of
Financial Condition and Results of Operations, both of which are
contained in our Annual Report on form 10-K filed with the
Securities and Exchange Commission, or SEC, on April 17, 2018.
Unless the context requires otherwise, references in this Quarterly
Report on Form 10-Q to “we,” “us,” and “our” refer to Genprex,
Inc.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Forward-Looking Statements</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
This Management’s Discussion and Analysis of Financial Condition
and Results of Operations (“MD&amp;A”) contains certain
forward-looking statements. Historical results may not indicate
future performance. Our forward-looking statements reflect our
current views about future events, are based on assumptions and are
subject to known and unknown risks and uncertainties that could
cause actual results to differ materially from those contemplated
by these statements. Factors that may cause differences between
actual results and those contemplated by forward- looking
statements include, but are not limited to, those discussed in 
“Risk Factors” as set forth in Part II, Item 1A, “Risk Factors” in
this Quarterly Report on Form 10-Q and in our other filings with
the SEC. We undertake no obligation to publicly update or revise
any forward-looking statements, including any changes that might
result from any facts, events, or circumstances after the date
hereof that may bear upon forward- looking statements. Furthermore,
we cannot guarantee future results, events, levels of activity,
performance, or achievements.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Overview</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Genprex™ is <font style="Background-color:#FFFFFF;">a clinical
stage gene therapy company developing a new approach to treating
cancer, based upon a novel proprietary technology platform,
including our initial product candidate, Oncoprex immunogene
therapy for non-small cell lung cancer (NSCLC). Our platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance</font>.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Researchers at MD Anderson have conducted a Phase I clinical trial
and the Phase I portion of a Phase I/II clinical trial and are
conducting the Phase II portion of that Phase I/II clinical trial
in non-small cell lung cancer, or NSCLC. MD Anderson researchers
have collaborated with other researchers to identify other genes,
such as those in the 3p21.3 chromosomal region, that may act as
tumor suppressors or have other cancer fighting functions. Data
from preclinical studies performed by others suggest that product
candidates that could be derived from our technology platform could
be effective against other types of cancer, including breast, head
and neck, renal cell (kidney), and soft tissue cancer, as well as
NSCLC. Therefore, our platform technologies may allow delivery of a
number of cancer fighting genes, alone or in combination with other
cancer therapies, to combat multiple types of cancer.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
JOBS Act and Recent Accounting Pronouncements</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The JOBS Act, enacted in 2012, provides that an “emerging growth
company” can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act of 1933, as
amended, for complying with new or revised accounting standards. In
other words, an “emerging growth company” can delay the adoption of
certain accounting standards until those standards would otherwise
apply to private companies. We have irrevocably elected not to
avail ourselves of this extended transition period and, as a
result, we will adopt new or revised accounting standards on the
relevant dates on which adoption of such standards is required for
other public companies.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We have implemented all new accounting pronouncements that are in
effect and may affect our condensed financial statements and we do
not believe that there are any other new accounting pronouncements
that have been issued that would have a material impact on our
financial position or results of operations.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Critical Accounting Policies and Significant Judgments and
Estimates</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU15" id=
"_AEIOULastRenderedPageBreakAEIOU15"></a>Our condensed financial
statements have been prepared in accordance with generally accepted
accounting principles in the United States, or GAAP. The
preparation of these condensed financial statements requires us to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and
liabilities at the date of the condensed financial statements, as
well as the reported expenses incurred during the reporting
periods. Our estimates are based on our historical experience and
on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
14</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
making ju</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dgments
about the carrying value of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or
conditions.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We believe that the following accounting policies are the most
critical to aid in fully understanding and evaluating our reported
financial results, and they require our most difficult, subjective
or complex judgments, resulting from the need to make estimates
about the effect of matters that are inherently
uncertain<font style="font-weight:bold;">.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Research and Development Costs</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We record accrued expenses for costs invoiced from research and
development activities conducted, on our behalf, by third-party
service providers, which include the conduct of pre-clinical
studies and clinical trials and contract manufacturing activities.
We record the costs of research and development activities based
upon the amount of services provided, and we include these costs in
accrued liabilities in the balance sheets and within research and
development expense in the statement of operations. These costs are
a significant component of our research and development
expenses.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We estimate the amount of work completed through discussions with
internal personnel and external service providers as to the
progress or stage of completion of the services and the agreed-upon
fee to be paid for such services. We make significant judgments and
estimates in determining the accrued balance in each reporting
period. As actual costs become known, we adjust our accrued
estimates. Although we do not expect our estimates to be materially
different from amounts actually incurred, our understanding of the
status and timing of services performed, the number of patients
enrolled and the rate of patient enrollment may vary from our
estimates and could result in us reporting amounts that are too
high or too low in any particular period. Our accrued expenses are
dependent, in part, upon the receipt of timely and accurate
reporting from clinical research organizations and other
third-party service providers. To date, there have been no material
differences from our accrued expenses to actual expenses.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Income Taxes</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Deferred tax assets or liabilities are recorded for temporary
differences between financial statement and tax basis of assets and
liabilities, using enacted rates in effect for the year in which
the differences are expected to reverse. A valuation allowance is
recorded if it is more likely than not that a deferred tax asset
will not be realized. We have provided a full valuation allowance
on our deferred tax assets, which primarily consist of cumulative
net operating losses from April 1, 2009 (inception) to March 31,
2018. Due to our history of operating losses since inception and
losses expected to be incurred in the foreseeable future, a full
valuation allowance was considered necessary.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Impairment of Long-Lived Assets</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Management reviews long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying amount may
not be realizable or at a minimum annually during the fourth
quarter of the year. If an evaluation is required, the estimated
future undiscounted cash flows associated with the asset are
compared to the asset’s carrying value to determine if an
impairment of such asset is necessary. The effect of any impairment
would be to expense the difference between the fair value of such
asset and its carrying value.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Components of our Results of Operations and Financial Condition</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Operating expenses</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We classify our operating expenses into three categories: research
and development, general and administrative and depreciation.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Research and development<font style=
"font-weight:normal;font-style:normal;">. Research and development
expenses consist primarily of:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">costs incurred to
conduct research, such as the discovery and development of our
current and potential product candidates;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">costs related to
production of clinical supplies, including fees paid to contract
manufacturers;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">fees paid to clinical
consultants, clinical trial sites and vendors, including clinical
research organizations in conjunction with implementing and
monitoring our clinical trials and acquiring and evaluating
clinical trial data, including all related fees, such as patient
screening fees, laboratory work and statistical compilation and
analysis; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">costs related to
compliance with drug development regulatory
requirements.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We recognize all research and development costs as they are
incurred. Clinical trial costs, contract manufacturing and other
development costs incurred by third parties are expensed as the
contracted work is performed.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
15</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU16" id=
"_AEIOULastRenderedPageBreakAEIOU16"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We
expect our research and development expenses to increase in the
future as we advance our current and potential product candidates
into and through clinical trials and pursue regulatory approval of
our current and potential product candidates in the</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
United States and Europe. The process of conducting the necessary
clinical research to obtain regulatory approval is costly and
time-consuming. The actual probability of success for our current
and potential product candidates may be affected by a
variety</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
of factors including the quality of our current and potential
product candidates, early clinical data, investment in our clinical
program, competition, manufacturing capability and commercial
viability. We may never succeed in achieving regulatory
approval</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
for any of our current and potential product candidates. As a
result of the uncertainties discussed above, we are unable to
determine the duration and completion costs of our research and
development projects or when and to what extent we will generate
re</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venue
from the commercialization and sale of our current and potential
product candidates.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
General and administrative<font style=
"font-weight:normal;">.</font> <font style=
"font-weight:normal;font-style:normal;">General and administrative
expense consists of personnel related costs, which include
salaries, as well as the costs of professional services, such as
accounting and legal, facilities, information technology and other
administrative expenses. We expect our general and administrative
expense to increase follwing the completion of our IPO due to the
anticipated growth of our business and related infrastructure as
well as accounting, insurance, investor relations and other costs
associated with being a public company.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Depreciation<font style="font-weight:normal;">.</font> <font style=
"font-weight:normal;font-style:normal;">Depreciation expense
consists of depreciation on our property and equipment. We
depreciate our assets over their estimated useful life. We estimate
computer and office equipment to have a 5-year life.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Results of Operations</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Comparison of the Three Months Ended March 31, 2018 and 2017</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The following summarizes our results of operations for the three
months ended March 31, 2018 and 2017.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Research and Development Expense</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Research and development expense consists primarily of costs
related to the discovery and development of our current and
potential product candidates; costs related to production of
clinical supplies, including fees paid to contract manufacturers,
fees paid to clinical consultants, clinical trial sites and
vendors, including clinical research organizations in conjunction
with implementing and monitoring our clinical trials and acquiring
and evaluating clinical trial data; and costs related to compliance
with drug development regulatory requirements.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Research and development expense was $51,621 for the three months
ended March 31, 2018 as compared to $68,364 for the three months
ended March 31, 2017. This decrease of $16,743 was primarily due to
the slowing of our clinical trial, during the first quarter of
2018, while we prepare our data, including pre-clinical data, data
from our completed Phase I clinical trial, and interim data from
our current Phase I/II clinical trial, for submission to the FDA in
anticipation of discussions concerning possible pathways for
obtaining marketing approval of Oncoprex for treatment of non-small
cell lung cancer.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
General and Administrative Expense</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
General and administrative expense primarily consists of personnel
costs, travel, information technology, facilities, and professional
service fees. Professional services fees primarily consist of
legal, accounting and consulting costs.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
General and administrative expense for the three months ended March
31, 2018 was $634,063 as compared to $682,342 for the three months
ended March 31, 2017. The $48,279 decrease in general and
administrative expense is mostly due to tightening of expenses
toward the end of our IPO in preparation for expansion directly
following the IPO.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We expect general and administrative expense to increase due to
additional legal, accounting, insurance, investor relations and
other costs associated with being a public company.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Interest Expense. <font style="font-weight:normal;">Interest
expense was $7,398 and $0 for each of the three month periods ended
March 31, 2018 and 2017. The increase in $7,398 was due to
short-term loans acquired by the Company at the end of 2018 and
during the first three months of 2018.</font></p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
16</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU17" id=
"_AEIOULastRenderedPageBreakAEIOU17"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Depreciation
Expense.</font> <font style="font-weight:normal;">Depreciation
expense was $</font><font style="font-weight:normal;">947</font>
<font style="font-weight:normal;">and $</font><font style=
"font-weight:normal;">597</font> <font style=
"font-weight:normal;">for the three months ended</font>
<font style="font-weight:normal;">March 31, 2018</font>
<font style="font-weight:normal;">and 201</font><font style=
"font-weight:normal;">7</font><font style="font-weight:normal;">,
respectively. Depreciation is generated from our fixed assets,
which consist only of computer equipment at this time.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Liquidity and Capital Resources</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
From our inception through March 31, 2018, we have never generated
revenue from product sales and have incurred net losses in each
year since inception. As of March 31, 2018, we had an accumulated
deficit of $18,146,352. We have funded our operations primarily
through the sale and issuance of capital stock. During 2017, we
sold 22,473 shares of Series G preferred stock at $35.33 per share
for a total of $793,971. This stock was subsequently converted to
150,211 shares of common stock at $5.29 per share prior to the
closing of our initial public offering.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As of March 31, 2018, we had $24,485 in cash.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We do not expect to generate revenue from product sales unless and
until we successfully complete development of, obtain regulatory
approval for and begin to commercialize one or more of our current
and potential product candidates, which we expect will take a
number of years and which is subject to significant uncertainty.
Accordingly, we anticipate that we will need to raise additional
capital to fund our future operations. Until such time as we can
generate substantial revenue from product sales, if ever, we expect
to finance our operating activities through a combination of equity
offerings and debt financings and we may seek to raise additional
capital through strategic collaborations. However, we may be unable
to raise additional funds or enter into such arrangements when
needed on favorable terms, or at all, which would have a negative
impact on our financial condition and could force us to delay,
limit, reduce or terminate our development programs or
commercialization efforts or grant to others rights to develop or
market product candidates that we would otherwise prefer to develop
and market ourselves. Failure to receive additional funding could
cause us to cease operations, in part or in full. Furthermore, even
if we believe we have sufficient funds for our current or future
operating plans, we may seek additional capital due to favorable
market conditions or strategic considerations.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The following table sets forth the primary sources and uses of cash
for the three months ended March 31, 2018 and 2017:</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Three Months ended March 31,</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2018</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
2017</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash used in operating activities</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(203,712</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(649,309</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash used in investing activities</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(10,452</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(22,978</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash provided by financing activities</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
77,398</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
—</p>
</td>
<td valign="bottom" bgcolor="#CFF0FC" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net increase (decrease) in cash and cash equivalents</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(136,766</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
$</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style=
"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(672,287</p>
</td>
<td valign="bottom" bgcolor="#FFFFFF" style=
"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
)</p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
Cash used in operating activities</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash used in operating activities was $203,712 and $649,309 for
the three months ended March 31, 2018 and 2017, respectively. The
$445,597 decrease in net cash used in operating activities was
primarily due to an increase in expenses related to our initial
public offering in the first quarter of 2018 compared to 2017 and
also an increase in payments made to professionals and
consultants.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
Cash used in investing activities</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash used in investing activities was $10,452 and $22,978 for
the three months ended March 31, 2018 and 2017, respectively. The
decrease of $12,526 was primarily due to increased patent
prosecution expenses in 2017.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
Cash provided by financing activities</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Net cash provided by financing activities was $77,398 and $0 during
the three months ended March 31, 2018 and, 2017, respectively. The
$77,398 increase in net cash provided by financing activities was
due to greater investment provided to the company during the 2018
year than the prior year.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
17</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="Item4.Controls" id="Item4.Controls"></a><a name=
"_bookmark8" id="_bookmark8"></a><a name="Item3.Quantitative" id=
"Item3.Quantitative"></a><a name="_bookmark7" id=
"_bookmark7"></a><a name="_AEIOULastRenderedPageBreakAEIOU18" id=
"_AEIOULastRenderedPageBreakAEIOU18"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item
4. Controls</font> <font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
and Procedures. Disclosure Controls and Procedures</font></p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Disclosure Controls and Procedures</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act,
our management with the participation of our Chief Executive
Officer and our Chief Financial Officer, evaluated the
effectiveness of our disclosure controls and procedures as of March
31, 2018. The term “disclosure controls and procedures” as defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means
controls and other procedures of a company that are designed to
ensure that information required to be disclosed by a company in
the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported, within the time
periods specified in the SEC’s rules and forms. Disclosure controls
and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by a
company in the reports that it files or submits under the Exchange
Act is accumulated and communicated to the company’s management,
including its principal executive and principal financial officer,
as appropriate to allow timely decisions regarding required
disclosure. Management recognizes that any controls and procedures,
no matter how well designed and operated, can provide only
reasonable assurance of achieving their objectives, and management
necessarily applies its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. Based on the
evaluation of our disclosure controls and procedures as of March
31, 2018, our Chief Executive Officer and our Chief Financial
Officer concluded that, as of such date, our disclosure controls
and procedures were effective at the reasonable assurance
level.</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Changes in Internal Control over Financial Reporting</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
There were no changes in our internal control over financial
reporting that occurred during the quarter ended March 31, 2018
that have materially affected, or are reasonably likely to
materially affect, our internal control over financial
reporting.</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Inherent Limitations of Disclosure Controls and Internal Control
over Financial Reporting</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Because of their inherent limitations, our disclosure controls and
procedures and our internal control over financial reporting may
not prevent material errors or fraud. A control system, no matter
how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are
met. The effectiveness of our disclosure controls and procedures
and our internal control over financial reporting is subject to
risks, including that the controls may become inadequate because of
changes in conditions or that the degree of compliance with our
policies or procedures may deteriorate.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
18</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU19" id=
"_AEIOULastRenderedPageBreakAEIOU19"></a><a name=
"PART_II_OR_INFORMATION" id=
"PART_II_OR_INFORMATION"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II_OR_INFORMATION"
id="PART_II_OR_INFORMATION"></a>PART II – OTHE</font><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">R
INFORMATION</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="Item1.Legal" id="Item1.Legal"></a>Item 1. Legal
Proceedings</p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We are not subject to any litigation.</p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In October 2017, we received an informal demand from a former
financial advisor, claiming that it is entitled to a warrant to
purchase shares of common stock equal to three percent of our
outstanding shares as of December 1, 2015, with “piggyback”
registration rights. We believe this asserted claim lacks merit,
and we intend to defend the claim vigorously. We have not reflected
any expense or any effect on our capitalization or otherwise
related to this demand because it is not yet possible to determine
whether any effect is probable or reasonably estimable.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="Item1A.Risk" id="Item1A.Risk"></a>Item 1A. Risk
Factors</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">
Investing in our common stock involves a high degree of risk. You
should carefully consider each of the following risks, together
with all other information set forth in this Quarterly Report on
Form 10-Q, including the condensed financial statements and the
related notes, before making a decision to purchase, hold or sell
our common stock. If any of the following risks actually occurs,
our business could be harmed. In that case, the trading price of
our common stock could decline, and you may lose all or part of
your investment.</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;color:#auto;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Risks Related to Our Financial Position and Need for Additional
Capital</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We will require substantial additional funding, which may not be
available to us on acceptable terms, or at all, and, if not so
available, may require us to delay, limit, reduce or cease our
operations.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We intend to use the proceeds from the recently completed initial
public offering and private placement of our securities to advance
Oncoprex through clinical development, as well as for other
purposes. Developing pharmaceutical products, including conducting
preclinical studies and clinical trials, is expensive. We will
require substantial additional future capital in order to complete
clinical development and commercialize Oncoprex. If the FDA
requires that we perform additional preclinical studies or clinical
trials, our expenses will further increase beyond what we currently
expect and the anticipated timing of any potential approval of
Oncoprex would likely be delayed. Further, there can be no
assurance that the costs we will need to incur to obtain regulatory
approval of Oncoprex will not increase.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We will continue to require substantial additional capital to
continue our clinical development and commercialization activities.
Because successful development of our current and potential product
candidates is uncertain, we are unable to estimate the actual
amount of funding we will require to complete research and
development and commercialize our products under development.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The amount and timing of our future funding requirements will
depend on many factors, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the progress, costs,
results and timing of our clinical trials for Oncoprex;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the outcome, costs and
timing of seeking and obtaining FDA and any other regulatory
approvals;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the ability of third
parties to deliver materials and provide services for
us;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the costs associated
with securing and establishing commercialization and manufacturing
capabilities;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">market acceptance of our
current and potential product candidates;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the costs of acquiring,
licensing or investing in businesses, products, product candidates
and technologies;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to maintain,
expand and enforce the scope of our intellectual property
portfolio, including the amount and timing of any payments we may
be required to make, or that we may receive, in connection with the
licensing, filing, prosecution, defense and enforcement of any
patents or other intellectual property rights;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our need and ability to
hire additional management and scientific and medical
personnel;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the effect of competing
drug candidates and new product approvals;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our need to implement
additional internal systems and infrastructure, including financial
and reporting systems; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the economic and other
terms, timing of and success of our existing licensing arrangements
and any collaboration, licensing or other arrangements into which
we may enter in the future.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
19</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU20" id=
"_AEIOULastRenderedPageBreakAEIOU20"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some
of these factors are outside of our control. We expect that the net
proceeds from the recently completed initial public offering</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
and private placement</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
of our</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
securities</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
and our existing cash</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
and marketable securities will be su</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fficient
to fund our current operations through at least the next
1</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
months. This period could be shortened if there are any significant
increases in planned spending on development programs or more rapid
progress of development programs than anticipated.</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We believe that our existing capital resources and the proceeds of
our initial public offering</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
and private placement may not</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
be sufficient to enable us to complete the development and
commercialization of Oncoprex. Accordingly, we expect that
we</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
may</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
need t</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o
raise additional funds in the future.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may seek additional funding through a combination of equity
offerings, debt financings, government or other third-party
funding, commercialization, marketing and distribution arrangements
and other collaborations, strategic alliances and licensing
arrangements. Additional funding may not be available to us on
acceptable terms or at all. In addition, the terms of any financing
may adversely affect the holdings or the rights of our
stockholders. Any new equity securities we issue could have rights,
preferences, and privileges superior to those of holders of our
existing capital stock. In addition, the issuance of additional
shares by us, or the possibility of such issuance, may cause the
market price of our shares to decline. Any debt financing secured
by us in the future could involve restrictive covenants relating to
our capital-raising activities and other financial and operational
matters, which may make it more difficult for us to obtain
additional capital and to pursue business opportunities.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we are unable to obtain funding on a timely basis, we may be
required to significantly curtail one or more of our research or
development programs, our ability to continue to support our
business growth and to respond to business challenges could be
significantly limited, and we could be forced to halt operations.
Accordingly, our business may fail, in which case you would lose
the entire amount of your investment in our common
stock.&nbsp;&nbsp;</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We also could be required to seek funds through arrangements with
collaborative partners or otherwise that may require us to
relinquish rights to some of our technologies or product candidates
or otherwise agree to terms unfavorable to us.</p>
<p style=
"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Our independent registered public accounting firm has indicated
that our financial condition raises substantial doubt as to our
ability to continue as a going concern.</p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our financial statements have been prepared assuming that we will
continue to operate as a going concern, which contemplates the
realization of assets and the satisfaction of liabilities in the
normal course of business. Our independent registered public
accounting firm included in its audit opinion for the years ended
December 31, 2017 and 2016 a statement that there is substantial
doubt as to our ability to continue as a going concern as a result
of our recurring losses and financial condition on December 31,
2017 and 2016, unless we are able to obtain additional financing,
enter into strategic alliances and/or sell assets. The reaction of
investors to the inclusion of a going concern statement by our
auditors, our current level of cash resources and our potential
inability to continue as a going concern may materially adversely
affect our share price and our ability to raise new capital or
enter into strategic alliances. If we become unable to obtain
additional capital and to continue as a going concern, we may have
to liquidate our assets and the values we receive for our assets in
liquidation or dissolution could be significantly lower than the
values reflected in our financial statements.&nbsp;</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We have never been profitable, we have no products approved for
commercial sale, and to date we have not generated any revenue from
product sales. As a result, our ability to reduce our losses and
reach profitability is unproven, and we may never achieve or
sustain profitability.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We have never been profitable and do not expect to be profitable in
the foreseeable future. We have not yet submitted any drug
candidates for approval by regulatory authorities in the United
States or elsewhere. From our inception on April 1, 2009, to March
31, 2018, we incurred an accumulated deficit of approximately $18.1
million. We incurred net losses of approximately $0.7 million and
approximately $3.3 million for the quarter ended March 31, 2018 and
the year ended December 31, 2017, respectively.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
To date, we have devoted most of our financial resources to our
corporate overhead and research and development, including our
preclinical development activities and clinical trials. We have not
generated any revenues from product sales. We expect to continue to
incur losses for the foreseeable future, and we expect these losses
to increase as we continue our development of, and seek regulatory
approvals for our current and potential product candidates, prepare
for and begin the commercialization of any approved products, and
add infrastructure and personnel to support our continuing product
development efforts. We anticipate that any such losses could be
significant for the next several years. If Oncoprex or any of our
other potential product candidates fails in clinical trials or does
not gain regulatory approval, or if our drug candidates do not
achieve market acceptance, we may never become profitable. As a
result of the foregoing, we expect to continue to experience net
losses and negative cash flows for the foreseeable future. These
net losses and negative cash flows have had, and will continue to
have, an adverse effect on our stockholders’ equity and working
capital.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU21" id=
"_AEIOULastRenderedPageBreakAEIOU21"></a>Because of the numerous
risks and uncertainties associated with pharmaceutical product
development, we are unable to accurately predict the timing or
amount of increased expenses or when, or if, we will be able to
achieve profitability. In addition, our expenses could increase if
we are required by the FDA to perform studies or trials in addition
to those currently expected, or if there</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
20</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
are any delays in completing our clinical trials or the development
of any of our drug candidates. The amount of future net losses will
depend, in part, on the rate of future growth of our expenses and
our ability to generate revenues.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We have a limited operating history and we expect a number of
factors to cause our operating results to fluctuate on an annual
basis, which may make it difficult to predict our future
performance.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We are a clinical stage gene therapy company with a limited
operating history. Our operations to date have been limited to
conducting clinical and preclinical research. We have not yet
obtained any regulatory approvals for any of our drug candidates.
Consequently, any predictions made about our future success or
viability may not be as accurate as they could be if we had a
longer operating history or approved products on the market. Our
operating results are expected to significantly fluctuate from
quarter to quarter and year to year due to a variety of factors,
many of which are beyond our control. Factors relating to our
business that may contribute to these fluctuations include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">any delays in regulatory
review and approval of our current and potential product candidates
in clinical development, including our ability to receive approval
from the FDA for Oncoprex;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">delays in the
commencement, enrollment and timing of clinical trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the success of our
clinical trials through all phases of clinical
development;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">potential side effects
of our current and potential product candidates that could delay or
prevent approval or cause an approved drug to be taken off the
market;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to obtain
additional funding to develop product candidates;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to identify
and develop additional drug candidates beyond Oncoprex;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">competition from
existing products or new products that continue to
emerge;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the ability of patients
or healthcare providers to obtain coverage or sufficient
reimbursement for our products;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to adhere to
clinical trial requirements directly or with third parties such as
contract research organizations, or CROs;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our dependency on
third-party manufacturers to manufacture our products and key
ingredients;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to establish
or maintain collaborations, licensing or other arrangements,
particularly with MD Anderson;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to defend
against any challenges to our intellectual property including,
claims of patent infringement;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to enforce
our intellectual property rights against potential
competitors;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to secure
additional intellectual property protection for our drug candidates
in development and associated technologies;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to attract
and retain key personnel to manage our business effectively;
and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">potential product
liability claims.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Accordingly, the results of any historical quarterly or annual
periods should not be relied upon as indications of future
operating performance.</p>
<p style=
"text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;color:#auto;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Risks Related to Development and Commercialization of Our Current
and Potential Product Candidates</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Our success depends greatly on the success of our development of
Oncoprex for the treatment of non-small cell lung cancer, and our
pipeline of product candidates beyond this lead indication is
extremely early stage and limited.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU22" id=
"_AEIOULastRenderedPageBreakAEIOU22"></a>At this time we are
actively pursuing development of only one product candidate,
Oncoprex for non-small cell lung cancer. Therefore, we are
dependent on the success of Oncoprex in the near term. We cannot
provide you any assurance that we will be able to successfully
advance Oncoprex through the development process, or that any
development problems we experience in the future will not cause
significant delays or unanticipated costs, or that such development
problems can be solved. We may also experience delays in developing
a sustainable, reproducible and scalable manufacturing process or
transferring that process to commercial partners, or developing or
validating product release assays in a timely manner, which may
prevent us from completing our clinical trials or commercializing
our products on a timely or profitable basis, if at all.
Immunotherapy, gene therapy and biopharmaceutical product
development is a highly speculative undertaking and involves a
substantial degree of uncertainty. Because Oncoprex and our other
potential product candidates are based upon novel technology, it is
difficult to predict whether, either as stand-alone therapies or in
combination with other drugs, they will show consistently favorable
results and to predict the time and cost of their development</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
21</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
and of subsequently obtaining regulatory approval. Few gene therapy
products have been approved in the United States or Europe. We may
find it difficult to enroll patients in our clinical studies, which
could delay or prevent clinica</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l
studies of our current and potential product candidates. We may
encounter delays in our clinical studies, or we may fail to
demonstrate safety and efficacy to the satisfaction of FDA and
other regulatory authorities. We may not be successful in our
effor</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts
to identify or discover additional product candidates, or to
develop product candidates that we have identified.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Negative public opinion and increased regulatory scrutiny of gene
therapy and genetic research may damage public perception of our
current and potential product candidates or adversely affect our
ability to conduct our business or obtain regulatory approvals for
our current and potential product candidates.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Public perception may be influenced by claims that gene therapy is
unsafe, and gene therapy may not gain the acceptance of the public
or the medical community. In particular, our success will depend
upon physicians specializing in the treatment of those diseases
that our current and potential product candidates target
prescribing treatments that involve the use of our current and
potential product candidates in lieu of, or in addition to,
existing treatments with which they are already familiar and for
which greater clinical data may be available. More restrictive
government regulations or negative public opinion would have a
negative effect on our business or financial condition and may
delay or impair the development and commercialization of our
current and potential product candidates or demand for any products
we may develop. Adverse events in our clinical trials, even if not
ultimately attributable to our current and potential product
candidates, and the resulting publicity could lead to increased
governmental regulation, unfavorable public perception, potential
regulatory delays in the testing or approval of our potential
product candidates, stricter labeling requirements for those
product candidates that are approved and a decrease in demand for
any such product candidates. Concern about the environmental spread
of our product, whether real or anticipated, may hinder the
commercialization of our products.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Delays in the commencement, enrollment and completion of clinical
trials could result in increased costs to us and delay or limit our
ability to obtain regulatory approval for Oncoprex and our other
potential product candidates.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Oncoprex has been tested in only one prior Phase I clinical study,
involving 31 patients. In that study, Oncoprex was tested as a
monotherapy. We believe that the best path for development is to
develop a combination therapy of Oncoprex in combination with
erlotinib and possibly other drugs. We have an ongoing Phase I/II
clinical trial testing Oncoprex in combination with erlotinib.
Enrollment was completed in March 2015 for the Phase I portion of
this clinical trial, in which 18 patients were enrolled. The Phase
II portion of our Phase I/II clinical trial is at an early stage,
with a limited number of patients enrolled, and the favorable
results observed so far may not continue in the current clinical
trial or be replicated in other clinical trials, especially those
involving larger numbers of patients. Even if the Phase I/II trial
is successful, success in early clinical studies may not be
indicative of results obtained in later studies. The results from
our Phase I/II trial may not demonstrate sufficient safety and
efficacy to support the submission of marketing approval for
Oncoprex. Before we request marketing approval, the FDA may require
us to conduct additional clinical studies, or evaluate subjects for
an additional follow-up. Unless an accelerated approval process is
allowed by the FDA, one or more Phase III studies is normally
required for approval.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Delays in the commencement, enrollment and/or completion of
clinical trials could increase our product development costs or
delay or limit the regulatory approval of our current and potential
product candidates. We do not know whether any future trials or
studies of our other potential product candidates will begin on
time or will be completed on schedule, if at all. The start or end
of a clinical study is often delayed or halted due to changing
regulatory requirements, changes in the proposed regulatory
approval pathway for a drug candidate, manufacturing challenges,
including delays or shortages in available drug product, required
clinical trial administrative actions, slower than anticipated
patient enrollment, changing standards of care, availability or
prevalence of use of a comparative drug or required prior therapy,
clinical outcomes or financial constraints. For instance, delays or
difficulties in patient enrollment or difficulties in retaining
trial participants can result in increased costs, longer
development times or termination of a clinical trial. Clinical
trials of a new product candidate require the enrollment of a
sufficient number of patients, including patients who are suffering
from the disease the product candidate is intended to treat and who
meet other eligibility criteria. Rates of patient enrollment are
affected by many factors, including the size of the patient
population, the eligibility criteria for the clinical trial, that
include the age and condition of the patients and the stage and
severity of disease, the nature of the protocol, the proximity of
patients to clinical sites and the availability of effective
treatments and/or availability of other investigational treatment
options for the relevant disease.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As the second phase of a Phase I/II clinical trial, MD Anderson
researchers are conducting a Phase II clinical trial evaluating
Oncoprex in combination with erlotinib in NSCLC. Enrollment
eligibility criteria for this clinical trial are broad and include
stage IV and recurrent NSCLC not potentially curable by
radiotherapy or surgery, whether or not the patients have received
prior chemotherapy, and whether or not they have an activating EGFR
mutation. The Phase II trial began in June 2015 and is ongoing at
MD Anderson. Ten patients have been entered and nine are evaluable
for response under the trial protocol, because they have received 2
or more cycles of treatment. Preliminary analysis of the data from
these patients further supported our belief that Oncoprex may
provide medical benefit in several subpopulations of NSCLC patients
for which there is an unmet medical need, and may provide pathways
for accelerated approval.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
22</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU23" id=
"_AEIOULastRenderedPageBreakAEIOU23"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As
a result of these initial findings, in April 2016, we suspended
enrollment of new patients in this Phase II clinical trial to
collect additional trial data and have it analyzed in order to seek
FDA guidance as to whe</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ther
the protocol for this clinical trial could be modified to expand
enrollment and also to divide the patients into cohorts with a view
toward seeking accelerated approval in one or more of these cohort
populations. We expect to present our findings to
t</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he
FDA within the next several months. Although the clinical trial is
currently closed to new patient enrollment, it is not terminated,
and is considered “ongoing” because activities such as patient
follow-up and further data collection and analysis
contin</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ue.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we reach an agreement with the FDA regarding expanded patient
enrollment and defined patient cohorts, then we plan to amend the
trial protocol accordingly and proceed with the amended protocol at
MD Anderson and several additional clinical trial
sites.&nbsp;&nbsp; Amendments to the Phase II clinical trial
protocol will require approval of the Investigational Review Board,
or IRB, of each site where the amended trial is conducted. If we do
not reach an agreement with the FDA on these changes, then we plan
to reopen enrollment in the current version of the Phase II trial
at MD Anderson and at additional clinical trial sites. In that
event, we will need to provide MD Anderson with plans and funding
to move ahead with the trial. Whether under the original protocol
or a revised protocol, we intend to use a portion of the proceeds
of the recently completed initial public offering of our common
stock to add additional clinical trial sites.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
A product candidate can unexpectedly fail at any stage of
preclinical and clinical development. The historical failure rate
for product candidates is high due to scientific feasibility,
safety, efficacy, changing standards of medical care and other
variables. The results from preclinical testing or early clinical
trials of a product candidate may not predict the results that will
be obtained in later phase clinical trials of the product
candidate. We, the FDA or other applicable regulatory authorities
may suspend clinical trials of a product candidate at any time for
various reasons, including, but not limited to, a belief that
subjects participating in such trials are being exposed to
unacceptable health risks or adverse side effects, or other adverse
initial experiences or findings. We may not have the financial
resources to continue development of, or to enter into
collaborations for, a product candidate if we experience any
problems or other unforeseen events that delay or prevent
regulatory approval of, or our ability to commercialize, product
candidates, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">inability to obtain
sufficient funds required for a clinical trial;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">inability to reach
agreements on acceptable terms with current or prospective contract
research organizations, or CROs, and trial sites, the terms of
which can be subject to extensive negotiation and may vary
significantly among different CROs and trial sites;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">negative or inconclusive
results from our clinical trials or the clinical trials of others
for product candidates similar to ours, leading to a decision or
requirement to conduct additional preclinical testing or clinical
trials or abandon a program;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">serious and unexpected
drug-related side effects experienced by subjects in our clinical
trials or by individuals using drugs similar to our current and
potential product candidates;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">conditions imposed by
the FDA or comparable foreign authorities regarding the scope or
design of our clinical trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">delays in enrolling
research subjects in clinical trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">high drop-out rates and
high fail rates of research subjects;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">inadequate supply or
quality of product candidate components or materials or other
supplies necessary for the conduct of our clinical
trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">greater than anticipated
clinical trial costs;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">poor effectiveness of
our current and potential product candidates during clinical
trials; or</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">unfavorable FDA or other
regulatory agency inspection and review of a clinical trial site or
vendor.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may have difficulty engaging or retaining clinical trial sites
and/or enrolling patients in our clinical trials, which could delay
or prevent development of our current and potential product
candidates.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU24" id=
"_AEIOULastRenderedPageBreakAEIOU24"></a>Identifying and qualifying
patients to participate in clinical trials of our current and
potential product candidates is critical to our success. The timing
of our clinical trials depends on the speed at which we can engage
and retain clinical trial sites and recruit patients to participate
in testing our current and potential product candidates. We have
experienced delays in some of our clinical trials in the past due
to difficulties with enrollment and we may experience similar
delays in the future. We have suspended enrollment of new patients
in the Phase II portion of our Phase I/II clinical trial evaluating
Oncoprex in combination with erlotinib in NSCLC, and we may
experience difficulties with enrollment upon reopening enrollment
for the trial under the current protocol or a modified protocol. If
patients are unwilling to participate in our clinical trials
because of negative publicity from adverse events in the industry
or in the trials for other third party product candidates, or for
other reasons, including competitive clinical trials for similar
patient populations,</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
23</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
the timeline for engaging sites, recruiting patients, conducting
studies and obtaining regulatory approval of potential products may
be delay</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed.
These delays could result in increased costs, delays in advancing
our product development, delays in testing the effectiveness of our
technology or termination of the clinical trials
altogether.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We or our clinical trial sites may not be able to identify, recruit
and enroll a sufficient number of patients, or those with the
required or desired characteristics in a clinical trial, to
complete our clinical trials in a timely manner. Patient enrollment
is affected by factors including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">severity of the disease
under investigation;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">design of the clinical
trial protocol, including the fact that certain of our clinical
trials are randomized to current treatments;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">size of the patient
population;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">eligibility criteria for
the clinical trial in question;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">perceived risks and
benefits of the product candidate under study;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">general level of
excitement for the treatment approach;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">comments on social
media;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">proximity and
availability of clinical trial sites for prospective
patients;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">availability of
competing therapies and clinical trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">efforts to facilitate
timely enrollment in clinical trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">patient referral
practices of physicians; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">ability to monitor
patients adequately during and after treatment.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We currently plan to seek initial marketing approval in the United
States and subsequently in Europe. We may not be able to initiate
or continue clinical trials if we cannot enroll a sufficient number
of eligible patients to participate in the clinical trials required
by the FDA or the European Medicines Agency, or EMA, or other
regulatory agencies. Our ability to successfully initiate, enroll
and complete a clinical trial in any foreign country is subject to
numerous risks unique to conducting business in foreign countries,
including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">difficulty in
establishing or managing relationships with CROs and
physicians;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">different standards for
the conduct of clinical trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our inability to locate
qualified local consultants, physicians and partners;
and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the potential burden of
complying with a variety of foreign laws, medical standards and
regulatory requirements, including the regulation of pharmaceutical
and biotechnology products and treatments.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we have difficulty enrolling a sufficient number of patients to
conduct our clinical trials as planned, we may need to delay, limit
or terminate ongoing or planned clinical trials, any of which would
have an adverse effect on our business.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
24</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU25" id=
"_AEIOULastRenderedPageBreakAEIOU25"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any
product candidate we advance through clinical trials may not have
favorable results in later clinical trials or receive
regulatory</font> <font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
approval.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Clinical failure can occur at any stage of our clinical
development. Clinical trials may produce negative or inconclusive
results, and we may decide, or regulators may require us, to
conduct additional clinical trials or nonclinical studies. In
addition, data obtained from trials and studies are susceptible to
varying interpretations, and regulators may not interpret our data
as favorably as we do, which may delay, limit or prevent regulatory
approval. Success in preclinical studies and early clinical trials
does not ensure that subsequent clinical trials will generate the
same or similar results or otherwise provide adequate data to
demonstrate the efficacy and safety of a product candidate.
Thirty-one patients were treated in our first Phase I clinical
trial of Oncoprex used as a monotherapy, and 28 patients have been
enrolled to date (out of a possible total of 57) in our current
Phase I/II clinical trial of Oncoprex in combination with erlotinib
in NSCLC. Of the 28 patients, 18 were enrolled in the Phase I
portion of the Phase I/II trial, and three of these 18 are also
enrolled in the Phase II portion. Safety and efficacy results to
date may not continue to be obtained as additional patients are
treated, and may not be duplicated in future clinical trials. A
number of companies in the pharmaceutical industry, including those
with greater resources and experience than ours, have suffered
significant setbacks in clinical trials, even after seeing
promising results in earlier clinical trials.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, the design of a clinical trial can determine whether
its results will support approval of a product and flaws in the
design of a clinical trial may not become apparent until the
clinical trial is well advanced. We may be unable to design and
execute a clinical trial to support regulatory approval. Further,
clinical trials of potential products often reveal that it is not
practical or feasible to continue development efforts.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If Oncoprex is found to be unsafe or lack efficacy, we will not be
able to obtain regulatory approval for it and our business would be
harmed.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In some instances, there can be significant variability in safety
and/or efficacy results between different trials of the same
product candidate due to numerous factors, including changes in
trial protocols, differences in composition of the patient
populations, adherence to the dosing regimen and other trial
protocols and the rate of dropout among clinical trial
participants. We do not know whether any clinical trials we or any
of our potential future collaborators may conduct will demonstrate
the consistent or adequate efficacy and safety that would be
required to obtain regulatory approval and market any products. If
we are unable to bring Oncoprex to market, or to acquire other
products that are on the market or can be developed, our ability to
create stockholder value will be limited.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Even if we obtain regulatory approval of our current and potential
product candidates, the products may not gain market acceptance
among physicians, patients, hospitals, cancer treatment centers,
third-party payors and others in the medical community.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Ethical, social and legal concerns about gene therapy and genetic
research could result in additional regulations restricting or
prohibiting the products and processes we may use. Even with the
requisite approvals, the commercial success of our current and
potential product candidates will depend in part on the medical
community, patients, and third-party payors accepting gene therapy
products in general, and our current and potential product
candidates in particular, as medically useful, cost-effective and
safe. Any product that we bring to the market may not gain market
acceptance by physicians, patients, third-party payors and others
in the medical community. If these products do not achieve an
adequate level of acceptance, we may not generate significant
product revenue and may not become profitable. The degree of market
acceptance of these product candidates, if approved for commercial
sale, will depend on a number of factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the clinical indications
for which our current and potential product candidates are
approved;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">physicians, hospitals,
cancer treatment centers and patients considering our current and
potential product candidates as a safe and effective
treatment;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the potential and
perceived advantages of our current and potential product
candidates over alternative treatments;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the prevalence and
severity of any side effects;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">product labeling or
product insert requirements of the FDA or other regulatory
authorities;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">limitations or warnings
contained in the labeling approved by the FDA;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the timing of market
introduction of our current and potential product candidates as
well as competitive products;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the cost of treatment in
relation to alternative treatments;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the availability of
adequate coverage, reimbursement and pricing by third-party payors
and government authorities;</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
25</p>
<hr style="page-break-after:always;width:100%;" />
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<a name="_AEIOULastRenderedPageBreakAEIOU26" id=
"_AEIOULastRenderedPageBreakAEIOU26"></a><font style=
"font-family:Times New Roman;">the willingness of patients to pay
out-of-pocket in the absence of coverage by third-party payors,
including government</font> <font style=
"font-family:Times New Roman;">authorities;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the willingness, ability
and availability of healthcare providers that can comply with the
transportation, handling, and temperature-controlled storage
requirements associated with our current and potential product
candidates;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">relative convenience and
ease of administration, including as compared to alternative
treatments and competitive therapies; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the effectiveness of our
sales and marketing efforts.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Even if a potential product displays a favorable efficacy and
safety profile in preclinical and clinical trials, market
acceptance of the product will not be known until after it is
launched. Our efforts to educate the medical community and
third-party payors on the benefits of the product candidates may
require significant resources and may never be successful. Such
efforts to educate the marketplace may require more resources than
are required by the conventional technologies marketed by our
competitors and may be restricted by the allowed label.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Our current and potential product candidates may have undesirable
side effects that may delay or prevent marketing approval, or, if
approval is received, require them to be taken off the market,
require them to include safety warnings or otherwise limit their
sales.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In our Phase I clinical trial of Oncoprex as a monotherapy, the
only serious adverse events, defined as grade 3, 4 or 5 events
under the Common Terminology Criteria for Adverse Events, or CTCAE,
published by the U.S. Department of Health and Human Services, were
grade 3 fever and grade 3 hypotension, and the only dose-limiting
toxicities were two episodes of transient grade 3 hypophosphatemia
(abnormally low levels of phosphate in the blood).</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The Phase I portion of our Phase I/II trial combining Oncoprex with
erlotinib was a dose escalation study with the primary purpose of
determining the MTD. Dose Limiting Toxicities were defined as grade
3, 4, or 5 events during the first cycle of treatment that were
considered to be treatment related. At dose level 1 (Oncoprex .045
mg/kg plus erlotinib 100 mg), one subject had grade 3 adverse
events of fatigue, muscle weakness, and hyponatremia (low sodium
level) considered to be related to the study treatment (erlotinib);
therefore, three additional subjects were treated at this dose
level (six subjects total), none of whom suffered a Dose Limiting
Toxicity. At dose level 2 (Oncoprex .06 mg/kg plus erlotinib 100
mg), there were no Dose Limiting Toxicities. At dose level 3
(Oncoprex .45 mg/kg plus erlotinib 150 mg), one subject had a grade
3 rash considered to be related to the study treatment (erlotinib);
therefore, an additional three subjects were treated at this dose
level (six subjects total). No additional subjects suffered a Dose
Limiting Toxicity at dose level 3. At dose level 4 (Oncoprex .06
mg/kg plus erlotinib 150 mg), there were no Dose Limiting
Toxicities; thus dose level 4 was determined to be the MTD. None of
the 10 subjects treated to date in the Phase II portion of the
Phase I/II trial suffered a Dose Limiting Toxicity.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Additional or unforeseen side effects from Oncoprex or any of our
other potential product candidates could arise either during
clinical development or, if approved, after the approved product
has been marketed. A showing that Oncoprex or any other product
candidate causes undesirable or unacceptable side effects could
interrupt, delay or halt clinical trials and result in the failure
to obtain or suspension or termination of marketing approval from
the FDA and other regulatory authorities, or result in marketing
approval from the FDA and other regulatory authorities only with
restrictive label warnings.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If any of our current and potential product candidates receives
marketing approval and we or others later identify undesirable or
unacceptable side effects caused by such products:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">regulatory authorities
may require the addition of labeling statements, specific warnings,
a contraindication or field alerts to physicians and
pharmacies;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">we may be required to
change instructions regarding the way the product is administered,
conduct additional clinical trials or change the labeling of the
product;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">we may be subject to
limitations on how we may promote the product;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">sales of the product may
decrease significantly;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">regulatory authorities
may require us to take our approved product off the
market;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">we may be subject to
litigation or product liability claims; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our reputation may
suffer.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
26</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU27" id=
"_AEIOULastRenderedPageBreakAEIOU27"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any
of these events could prevent us or our potential future
collaborators from achieving or maintaining market acceptance of
the affected product or could substantially increase
commercialization costs and expenses, which in turn could delay or
prevent us</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
from generating significant revenues from the sale of our
products.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may face product liability claims.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In the event Oncoprex or any of our other potential product
candidates is approved for marketing by the FDA and other
regulatory authorities, we may face potential product liability. If
successful claims are brought against us, we may incur substantial
liability and costs. If the use of our current and potential
product candidates harms patients, or is perceived to harm patients
even when such harm is unrelated to our current and potential
product candidates, our regulatory approvals could be revoked or
otherwise negatively impacted, and we could be subject to costly
and damaging product liability claims.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Our internal computer systems, or those used by our CROs,
contractors or consultants, may fail or suffer security
breaches.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Despite the implementation of security measures, our internal
computer systems and those of our CROs, contractors and consultants
are vulnerable to damage from computer viruses and unauthorized
access, as well as being vulnerable to other system difficulties,
failures or disruptions. If such an event were to occur and cause
interruptions in our operations, it could result in a material
disruption of our development programs and our business operations.
For example, the loss of clinical trial data from completed or
future clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or
reproduce the data. To the extent that any disruption or security
breach were to result in a loss of, or damage to, our data or
applications, or inappropriate disclosure of confidential or
proprietary information, we could incur liability, and the further
development and commercialization of our current and potential
product candidates could be delayed.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Business disruptions could seriously harm our future revenue and
financial condition and increase our costs and expenses.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our operations, and those of our CROs, contractors and consultants,
could be subject to power shortages, telecommunications failures,
wildfires, water shortages, floods, earthquakes, hurricanes,
typhoons, fires, extreme weather conditions, medical epidemics and
other natural or man-made disasters or business interruptions. The
occurrence of any of these business disruptions could seriously
harm our operations and financial condition and increase our costs
and expenses. Our ability to obtain clinical supplies of our
current and potential product candidates could be disrupted if the
operations of our contract manufacturers are affected by a man-made
or natural disaster or other business interruption. Unfavorable
global economic conditions could adversely affect our business,
financial condition, or results of operations.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We do not carry insurance for all categories of risk that our
business may encounter. In particular, we do not carry product
liability insurance covering any clinical trials liability that we
may incur. Although we intend to obtain such insurance before we
market any product, there can be no assurance that we will secure
adequate insurance coverage or that any such insurance coverage
will be sufficient to protect our operations to significant
potential liability in the future. Any significant uninsured
liability may require us to pay substantial amounts, which would
adversely affect our financial position and results of
operations.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We face competition from other biotechnology and pharmaceutical
companies and our operating results will suffer if we fail to
compete effectively.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The biotechnology and pharmaceutical industries are intensely
competitive and subject to rapid and significant technological
change. We have competitors in the United States, Europe and
elsewhere, including major multinational pharmaceutical companies,
established biotechnology companies, specialty pharmaceutical and
generic drug companies and universities and other research
institutions. Many of our competitors have greater financial and
other resources, such as larger research and development staff and
more experienced marketing and manufacturing organizations than we
do. Large pharmaceutical companies, in particular, have extensive
experience in clinical testing, obtaining regulatory approvals,
recruiting patients and manufacturing pharmaceutical products.
These companies also have significantly greater research, sales and
marketing capabilities and collaborative arrangements in our target
markets with leading companies and research institutions.
Established pharmaceutical companies may also invest heavily to
accelerate discovery and development of novel compounds or to
in-license novel compounds that could make the product candidates
that we develop obsolete. As a result of these factors, our
competitors may succeed in obtaining patent protection and/or FDA
approval or discovering, developing and commercializing drugs for
the cancer indications that we are targeting before we do or may
develop drugs that are deemed to be more effective or gain greater
market acceptance than ours. Smaller or early-stage companies may
also prove to be significant competitors, particularly through
collaborative arrangements with large, established companies. In
addition, many universities and private and public research
institutes may become active in our target disease areas. Our
competitors may succeed in developing, acquiring or licensing on an
exclusive basis, technologies and drug products that are more
effective or less costly than any product candidates that we are
currently developing or that we may develop, which could render our
products obsolete or noncompetitive.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU28" id=
"_AEIOULastRenderedPageBreakAEIOU28"></a>There are a number of
drugs approved and under development for treatment of lung cancer.
Treatments competitive with our primary product candidates
generally fall into the following categories: chemotherapies such
as cisplatin, carboplatin, docetaxel and</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
27</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
pemetrexed; targeted therapies such as erlotinib, gefitinib,
afatinib and osimertinib (marketed as Tagrisso® by AstraZeneca
Pharmaceuticals), and immunotherapies such as checkpoint inhibitors
and CAR</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
and CAR T cells, and oncolytic virus-based technology. Data
indicate that Oncoprex, when combined with certain targeted
therapies and immunotherapies, may enhance the benefit of those
therapies; therefore, we believe that Oncoprex could be
administered in</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
combination with targeted therapies and immunotherapies and thus
may not be a direct competitor of those drugs. In addition, new
drug candidates are constantly being conceived and developed. Any
such competing therapy may be more effective and/or
cost-eff</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ective
than ours.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If our competitors market products that are more effective, safer
or less expensive or that reach the market sooner than our future
products, if any, we may not achieve commercial success. In
addition, because of our limited resources, it may be difficult for
us to stay abreast of the rapid changes in each technology. If we
fail to stay at the forefront of technological change, we may be
unable to compete effectively. Technological advances or products
developed by our competitors may render our technologies or product
candidates obsolete, less competitive or not economical.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Risks Related to Regulatory Approval and Marketing of Our Current
and Potential Product Candidates and Other Legal Compliance
Matters</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We cannot be certain that Oncoprex will receive regulatory
approval, and without regulatory approval we will not be able to
market Oncoprex.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our business currently depends largely on the successful
development and commercialization of Oncoprex. Our ability to
generate revenue related to product sales, if ever, will depend on
the successful development and regulatory approval of Oncoprex for
the treatment of cancer. Even if we complete the necessary clinical
studies, we cannot predict when or if we will obtain regulatory
approval to commercialize a product candidate. Further, if we do
obtain regulatory approval, it may only apply to a more narrow
indication than we expect. Even if we obtain regulatory approval
for a product candidate, our products will remain subject to
regulatory scrutiny.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We currently have no products approved for sale and we cannot
guarantee that we will ever have marketable products. The
development of a product candidate and issues relating to its
approval and marketing are subject to extensive regulation by the
FDA in the United States and regulatory authorities in other
countries, with regulations differing from country to country. We
are not permitted to market our current and potential product
candidates in the United States until we receive approval of a
Biologics License Application, or BLA, from the FDA. We have not
submitted any marketing applications for any of our current and
potential product candidates.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
BLAs must include extensive preclinical and clinical data and
supporting information to establish the product candidate’s safety
and effectiveness for each desired indication. BLAs must also
include significant information regarding the chemistry,
manufacturing and controls for the product. Obtaining approval of a
BLA is a lengthy, expensive and uncertain process, and we may not
be successful in obtaining approval. The FDA review processes can
take years to complete and approval is never guaranteed. If we
submit a BLA to the FDA, the FDA must decide whether to accept or
reject the submission for filing. We cannot be certain that any
submissions will be accepted for filing and review by the FDA.
Regulators in other jurisdictions have their own procedures for
approval of product candidates. Even if a product is approved, the
FDA may limit the indications for which the product may be
marketed, require extensive warnings on the product labeling or
require expensive and time-consuming clinical trials or reporting
as conditions of approval. Regulatory authorities in countries
outside of the United States and Europe also have requirements for
approval of drug candidates with which we must comply with prior to
marketing in those countries. Obtaining regulatory approval for
marketing of a product candidate in one country does not ensure
that we will be able to obtain regulatory approval in any other
country. In addition, delays in approvals or rejections of
marketing applications in the United States, Europe or other
countries may be based upon many factors, including regulatory
requests for additional analyses, reports, data, preclinical
studies and clinical trials, regulatory questions regarding
different interpretations of data and results, changes in
regulatory policy during the period of product development and the
emergence of new information regarding our current and potential
product candidates or other products. Also, regulatory approval for
any of our current and potential product candidates may be
withdrawn.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we are unable to obtain approval from the FDA, or other
regulatory agencies, for Oncoprex, or if, subsequent to approval,
we are unable to successfully commercialize Oncoprex or our other
potential product candidates, we will not be able to generate
sufficient revenue to become profitable or to continue our
operations.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, the clinical trial requirements of the FDA, the
European Medicines Agency, or EMA, and other regulatory agencies
and the criteria these regulators use to determine the safety and
efficacy of a product candidate vary substantially according to the
type, complexity, novelty and intended use and market of the
potential products. The regulatory approval process for novel
product candidates such as ours can be more expensive and take
longer than for other, better known or extensively studied
pharmaceutical or other product candidates.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
28</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU29" id=
"_AEIOULastRenderedPageBreakAEIOU29"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reg</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ulatory
requirements governing gene therapy products have changed
frequently and may continue to change in the future. For example,
in January 2017, the FDA Oncology Center of Excellence, or the
Center of Excellence, was created to leverage the combined
sk</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ills
of regulatory scientists and reviewers with expertise in drugs,
biologics, and devices (including diagnostics). While the Center of
Excellence is designed to help expedite the development of oncology
and malignant hematology-related medical products
a</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd
support an integrated approach in the clinical evaluation of drugs,
biologics and devices for the treatment of cancer, the new Center
of Excellence may initially create confusion within the FDA and
especially in the Center of Biologics and Research that</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
is the primary review division for Oncoprex. Gene therapy clinical
trials conducted at institutions that receive funding for
recombinant DNA research from the U.S. National Institutes of
Health, or the NIH, are also subject to review by the NIH Office
of</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Biotechnology Activities’ Recombinant DNA Advisory Committee, or
the RAC. Although the FDA decides whether individual gene therapy
protocols may proceed, the RAC review process can impede the
initiation of a clinical trial, even if the FDA has reviewed
the</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
study and approved its initiation. Conversely, the FDA can put an
Investigational New Drug application, or IND, on a partial or
complete clinical hold even if the RAC has provided a favorable
review. Also, before a clinical trial can begin at an
NIH-funde</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d
institution, that institution’s institutional review board, or IRB,
and its Institutional Biosafety Committee will have to review the
proposed clinical trial to assess the safety of the study. In
addition, adverse developments in clinical trials of gene</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
therapy products conducted by others may cause the FDA or other
regulatory bodies to change the requirements for performing studies
or for obtaining approval of any of our current and potential
product candidates.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
These regulatory review committees and advisory groups, and the new
guidelines they promulgate, may lengthen the regulatory review
process, require us to perform additional studies, increase our
development costs, lead to changes in regulatory positions and
interpretations, delay or prevent approval and commercialization of
our current and potential product candidates or lead to significant
post-approval limitations or restrictions. As we advance our
current and potential product candidates, we will be required to
consult with these regulatory and advisory groups and comply with
applicable guidelines. Delay or failure to obtain, or unexpected
costs in obtaining, the regulatory approval necessary to bring a
potential product to market could decrease our ability to generate
sufficient revenue to maintain our business.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
If the FDA does not find the manufacturing facilities of our future
contract manufacturers acceptable for commercial production, we may
not be able to commercialize any of our current and potential
product candidates.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We do not intend to manufacture the pharmaceutical products that we
plan to sell. We are currently utilizing contract manufacturers for
the production of the active pharmaceutical ingredients and the
formulation of drug product for the trials of Oncoprex currently
being conducted or will need to be conducted prior to seeking
regulatory approval. However, we do not have agreements for
supplies of Oncoprex or any of our other potential product
candidates and we may not be able to reach agreements with these or
other contract manufacturers for sufficient supplies to
commercialize Oncoprex if it is approved. Additionally, the
facilities used by any contract manufacturer to manufacture
Oncoprex or any of our other potential product candidates must be
the subject of a satisfactory inspection before the FDA approves
the product candidate manufactured at that facility. We are
completely dependent on these third-party manufacturers for
compliance with the requirements of U.S. and non-U.S. regulators
for the manufacture of our finished products. If our manufacturers
cannot successfully manufacture materials that conform to our
specifications and the FDA’s current good manufacturing practices,
or cGMP, standards and other requirements of any governmental
agency to whose jurisdiction we are subject, our current and
potential product candidates will not be approved or, if already
approved, may be subject to recalls. Reliance on third-party
manufacturers entails risks to which we would not be subject if we
manufactured our current and potential product candidates,
including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the possibility that we
are unable to enter into a manufacturing agreement with a third
party to manufacture our current and potential product
candidates;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the possible breach of
the manufacturing agreements by the third parties because of
factors beyond our control; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the possibility of
termination or nonrenewal of the agreements by the third parties
before we are able to arrange for a qualified replacement
third-party manufacturer.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Any of these factors could cause the delay of approval or
commercialization of our current and potential product candidates,
cause us to incur higher costs or prevent us from commercializing
our current and potential product candidates successfully.
Furthermore, if any of our current and potential product candidates
are approved and contract manufacturers fail to deliver the
required commercial quantities of finished product on a timely
basis at commercially reasonable prices and we are unable to find
one or more replacement manufacturers capable of production at a
substantially equivalent cost, in substantially equivalent volumes
and quality and on a timely basis, we would likely be unable to
meet demand for our products and could lose potential revenue. It
may take several years to establish an alternative source of supply
for our current and potential product candidates and to have any
such new source approved by the government agencies that regulate
our products.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
29</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU30" id=
"_AEIOULastRenderedPageBreakAEIOU30"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We
may be subject, directly or indirectly, to federal and state
healthcare fraud a</font><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">nd
abuse laws, false claims laws and other federal and state
healthcare laws, and the failure to comply with such laws could
result in substantial penalties. Our employees, independent
contractors, consultants, principal investigators, CROs, commercial
par</font><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">tners
and vendors may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and
requirements.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We are exposed to the risk of fraud, misconduct or other illegal
activity by our employees, independent contractors, consultants,
principal investigators, CROs, commercial partners and vendors.
Misconduct by these parties could include intentional, reckless
and/or negligent conduct that fails to: comply with the laws of the
FDA and similar foreign regulatory bodies; provide true, complete
and accurate information to the FDA and similar foreign regulatory
bodies; comply with manufacturing standards we have established;
comply with federal and state data privacy, security, fraud and
abuse and other healthcare laws and regulations in the United
States and similar foreign fraudulent misconduct laws; or report
financial information or data accurately or to disclose
unauthorized activities to us. If we obtain FDA approval for any of
our current and potential product candidates and begin
commercializing those products in the United States, our potential
exposure under such laws would increase significantly, and our
costs associated with compliance with such laws would likely also
increase. These laws may impact, among other things, our current
activities with principal investigators and research patients, as
well as proposed and future sales, marketing and education
programs. In particular, the promotion, sales and marketing of
healthcare items and services, as well as certain business
arrangements in the healthcare industry, are subject to extensive
laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and
regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, including off-label uses of
our products, structuring and commission(s), certain customer
incentive programs and other business arrangements generally.
Activities subject to these laws also involve the improper use or
misrepresentation of information obtained in the course of patient
recruitment for clinical trials, creating fraudulent data in our
preclinical studies or clinical trials or illegal misappropriation
of drug product, which could result in regulatory sanctions and
cause serious harm to our reputation. It is not always possible to
identify and deter misconduct by employees and other third parties,
and the precautions we take to detect and prevent this activity may
not be effective in controlling unknown or unmanaged risks or
losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to comply with
these laws or regulations. Additionally, we are subject to the risk
that a person or government could allege such fraud or other
misconduct, even if none occurred. If any such actions are
instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a
significant impact on our business, including the imposition of
fines or other sanctions. The laws that may affect our ability to
operate include, but are not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the Federal
Anti-Kickback Statute, which prohibits, among other things,
individuals and entities from knowingly and willfully soliciting,
receiving, offering or paying any remuneration (including any
kickback, bribe, or rebate), directly or indirectly, overtly or
covertly, in cash or in kind, to induce, or in return for, either
the referral of an individual for, or the purchase, lease, order or
recommendation of, any good, facility, item or service for which
payment may be made, in whole or in part, under a federal
healthcare program, such as the Medicare and Medicaid programs. A
person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed
a violation;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">federal civil and
criminal false claims laws and civil monetary penalty laws,
including the civil False Claims Act, which impose criminal and
civil penalties, through government, civil whistleblower or qui tam
actions, on individuals and entities for, among other things,
knowingly presenting, or causing to be presented, claims for
payment or approval from Medicare, Medicaid, or other third-party
payors that are false, fictitious or fraudulent, or knowingly
making, using or causing to be made or used, a false statement to
avoid, decrease or conceal an obligation to pay money to the
federal government. In addition, the government may assert that a
claim including items and services resulting from a violation of
the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the False Claims Act;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the Federal Health
Insurance Portability and Accountability Act of 1996, or HIPAA,
which imposes criminal and civil liability for, among other things,
knowingly and willfully executing, or attempting to execute, a
scheme to defraud or to obtain any healthcare benefit program or
obtain, by means of false or fraudulent pretenses, representations,
or promises, any of the money or property owned by, or under the
custody or control of, any healthcare benefit program, regardless
of the payor (e.g., public or private), willfully obstructing a
criminal investigation of a healthcare offense, and knowingly and
willfully falsifying, concealing or covering up by any trick or
device a material fact or making any materially false, fictitious
or fraudulent statements in connection with the delivery of, or
payment for, healthcare benefits, items or services relating to
healthcare matters. Similar to the federal Anti-Kickback Statute, a
person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed
a violation;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act
of 2009, or HITECH, and their respective implementing regulations,
which impose requirements on certain covered healthcare providers,
health plans, and healthcare clearinghouses, as well as their
respective business associates that perform services for them that
involve the creation, use, maintenance or disclosure of,
individually identifiable health information, relating to the
privacy, security and transmission of individually identifiable
health information without appropriate authorization;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<a name="_AEIOULastRenderedPageBreakAEIOU31" id=
"_AEIOULastRenderedPageBreakAEIOU31"></a><font style=
"font-family:Times New Roman;">the federal physician payment
transparency requirements, sometimes referred to as the “Physician
Payments Sunshine Act,” created under the Patient Protection and
Affordable Care Act, as amended by the Health Care and
Education</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
30</p>
<hr style="page-break-after:always;width:100%;" />
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">R</font><font style=
"font-family:Times New Roman;">econciliation Act, collectively the
Affordable Care Act, and its implementing regulations, which
require certain manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare,
Medicaid or the Children’s Healt</font><font style=
"font-family:Times New Roman;">h Insurance Program (with certain
exceptions) to report annually to the United States Department of
Health and Human Services information related to payments or other
transfers of value made to physicians (defined to include doctors,
dentists, optometrists</font><font style=
"font-family:Times New Roman;">, podiatrists and chiropractors) and
teaching hospitals, as well as ownership and investment interests
held by physicians and their immediate family members;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the U.S. Federal Food,
Drug and Cosmetic Act, or FDCA, which prohibits, among other
things, the adulteration or misbranding of drugs and medical
devices; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">federal consumer
protection and unfair competition laws, which broadly regulate
marketplace activities and activities that potentially harm
consumers. Additionally, we are subject to state and foreign
equivalents of each of the healthcare laws described above, among
others, some of which may be broader in scope and may apply
regardless of the payor.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
It is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent
inappropriate conduct may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure
to be in compliance with such laws or regulations. Efforts to
ensure that our business arrangements will comply with applicable
healthcare laws and regulations will involve substantial costs. It
is possible that governmental and enforcement authorities will
conclude that our business practices may not comply with current or
future statutes, regulations or case law interpreting applicable
fraud and abuse or other healthcare laws and regulations. If any
such actions are instituted against us, and we are not successful
in defending ourselves or asserting our rights, those actions could
have a significant impact on our business, including the imposition
of civil, criminal and administrative penalties, damages,
disgorgement, monetary fines, possible exclusion from participation
in Medicare, Medicaid and other federal healthcare programs,
contractual damages, reputational harm, diminished profits and
future earnings, and curtailment or restructuring of our
operations, any of which could adversely affect our ability to
operate our business and our results of operations. In addition,
the approval and commercialization of any of our current and
potential product candidates outside the United States will also
likely subject us to foreign equivalents of the healthcare laws
mentioned above, among other foreign laws.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Coverage and reimbursement may be limited or unavailable in certain
market segments for our current and potential product candidates,
if approved, which could make it difficult for us to sell our
current and potential product candidates profitably.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The commercial success of any current or future product candidate
will depend upon the degree of market acceptance by physicians,
patients, insurance companies and other third party payors, and
others in the medical community. Even if we obtain approval to
commercialize our current and potential product candidates outside
of the United States, a variety of risks associated with
international operations could materially affect our business. Due
to the novel nature of our technology, we face uncertainty related
to pricing and reimbursement for our current and potential product
candidates. The insurance coverage and reimbursement status of
newly approved products is uncertain. Failure to obtain or maintain
adequate coverage and reimbursement for new or current products
could limit our ability to market those products and decrease our
ability to generate revenue. If market opportunities for our
current and potential product candidates are smaller than we
believe they are, our revenues may be adversely affected and our
business may suffer.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Successful sales of our products, if our current and potential
product candidates are approved, depend on the availability of
coverage and adequate reimbursement from third-party payors. In
addition, because our current and potential product candidates
represent new approaches to the treatment of cancer, we cannot be
sure that coverage and reimbursement will be available for, or
accurately estimate the potential revenue from, our current and
potential product candidates. Patients who are provided medical
treatment for their conditions generally rely on third-party payors
to reimburse all or part of the costs associated with their
treatment. Coverage and adequate reimbursement from governmental
healthcare programs, such as Medicare and Medicaid, and commercial
payors are critical to new product acceptance.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Government authorities and other third-party payors, such as
private health insurers and health maintenance organizations,
decide which drugs and treatments they will cover and the amount of
reimbursement. Coverage and reimbursement by a third-party payor
may depend upon a number of factors, including, but not limited to,
the third-party payor’s determination that use of a product is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">a covered benefit under
its health plan;&nbsp;&nbsp;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">safe, effective and
medically necessary;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">appropriate for the
specific patient;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">cost-effective;
and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">neither experimental nor
investigational.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
31</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU32" id=
"_AEIOULastRenderedPageBreakAEIOU32"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In
the United States, no uniform policy of coverage and reimbursement
for products exists among third-party payors</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,
and coverage and reimbursement for products can differ
significantly from payor to payor. As a result, obtaining coverage
and reimbursement approval of a product from a government or other
third-party payor is a time-consuming and costly process that
cou</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ld
require us to provide to each payor supporting scientific, clinical
and cost-effectiveness data for the use of our products and to
justify the level of coverage and reimbursement relative to other
therapies, with no assurance that coverage and adequate</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
reimbursement will be obtained. Third party payors may also have
difficulty in determining the appropriate coverage of Oncoprex and
our other potential product candidates that are combination
products, if approved, due to the fact that they are
combination</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
products that include another drug. To the extent there are any
delays in determining such coverage or inadequate coverage and
reimbursement for all aspects of our combination therapies, it
would adversely affect the market acceptance, demand and use of
o</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ur
current and potential product candidates. Any denial in coverage or
reduction in reimbursement from Medicare or other government
programs may result in a similar denial or reduction in payments
from private payors, which may adversely affect our future</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
profitability.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We intend to seek approval to market our current and potential
product candidates in both the United States and in selected
foreign jurisdictions. If we obtain approval in one or more foreign
jurisdictions for our current and potential product candidates, we
will be subject to rules and regulations in those jurisdictions. In
some foreign countries, particularly those in the European Union,
the pricing of biologics is subject to governmental control and
other market regulations which could put pressure on the pricing
and usage of our current and potential product candidates. In these
countries, pricing negotiations with governmental authorities can
take considerable time after obtaining marketing approval of a
product candidate. In addition, market acceptance and sales of our
current and potential product candidates will depend significantly
on the availability of coverage and adequate reimbursement from
third-party payors for our current and potential product candidates
and may be affected by existing and future health care reform
measures.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Healthcare legislative reform measures may have a material adverse
effect on our business and results of operations.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Third-party payors, whether domestic or foreign, or governmental or
commercial, are developing increasingly sophisticated methods of
controlling healthcare costs. In both the United States and certain
foreign jurisdictions, there have been a number of legislative and
regulatory changes to the health care system that could affect our
ability to sell our products profitably. In particular, in 2010,
the Affordable Care Act was enacted in the United States. The
Affordable Care Act and its implementing regulations, among other
things, subjected biological products to potential competition by
lower-cost biosimilars, revised the methodology by which rebates
owed by manufacturers to the state and federal government for
covered outpatient drugs and certain biologics, including our
current and potential product candidates, under the Medicaid Drug
Rebate Program are calculated, increased the minimum Medicaid
rebates owed by most manufacturers under the Medicaid Drug Rebate
Program, extended the Medicaid Drug Rebate program to utilization
of prescriptions of individuals enrolled in Medicaid managed care
organizations, subjected manufacturers to new annual fees and taxes
for certain branded prescription drugs, and provided incentives to
programs that increase the federal government’s comparative
effectiveness research. The current Presidential Administration and
U.S. Congress may seek to modify, repeal, or otherwise invalidate
all, or certain provisions of, the Affordable Care Act. There have
been judicial and Congressional challenges to certain aspects of
the Affordable Care Act. As a result, there have been delays in the
implementation of, and action taken to repeal or replace, certain
aspects of the Affordable Care Act. While the extent to which any
such changes may affect our business is uncertain, steps have been
taken to repeal and replace certain aspects of the Affordable Care
Act.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Since January 2017, President Trump has signed two Executive Orders
designed to delay the implementation of certain provisions of the
Affordable Care Act or otherwise circumvent some of the
requirements for health insurance mandated by the Affordable Care
Act. Concurrently, Congress has considered legislation that would
repeal or repeal and replace all or part of the Affordable Care
Act. While Congress has not passed comprehensive repeal
legislation, two bills affecting the implementation of certain
taxes under the Affordable Care Act have been signed into law. The
Tax Cuts and Jobs Act of 2017 includes a provision repealing,
effective January 1, 2019, the tax-based shared responsibility
payment imposed by the Affordable Care Act on certain individuals
who fail to maintain qualifying health coverage for all or part of
a year that is commonly referred to as the “individual mandate”.
Additionally, on January 22, 2018, President Trump signed a
continuing resolution on appropriations for fiscal year 2018 that
delayed the implementation of certain Affordable Care Act-mandated
fees, including the so-called “Cadillac” tax on certain high cost
employer-sponsored insurance plans, the annual fee imposed on
certain health insurance providers based on market share, and the
medical device excise tax on non-exempt medical devices. Further,
the Bipartisan Budget Act of 2018, or the BBA, among other things,
amends the Affordable Care Act, effective January 1, 2019, to close
the coverage gap in most Medicare drug plans, commonly referred to
as the “donut hole”. Congress also could consider subsequent
legislation to repeal or repeal and replace other elements of the
Affordable Care Act. We continue to evaluate the possible impact of
the Affordable Care Act, as amended, and the possible repeal and/or
replacement of the Affordable Care Act on our business.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
32</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU33" id=
"_AEIOULastRenderedPageBreakAEIOU33"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There
have been, and likely will continue to be, legislative and
regulatory proposals at the foreign, federal and state levels
directed at broade</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ning
the availability of healthcare and containing or lowering the cost
of healthcare. We cannot predict the initiatives that may be
adopted in the future. The continuing efforts of the government,
insurance companies, managed care organizations and other</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
payors of healthcare services to contain or reduce costs of
healthcare and/or impose price controls may adversely
affect:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the demand for our
current and potential product candidates, if we obtain regulatory
approval;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to set a
price that we believe is fair for our products;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our ability to generate
revenue and achieve or maintain profitability;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the level of taxes that
we are required to pay; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the availability of
capital.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We and our contract manufacturers are subject to significant
regulation with respect to manufacturing our products. The
manufacturing facilities on which we rely may not continue to meet
regulatory requirements and have limited capacity.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We are currently utilizing contract manufacturers for the
production of the active pharmaceutical ingredients and the
formulation of drug product for our trials of Oncoprex. However, we
do not have agreements for supplies of Oncoprex or any of our other
potential product candidates. Each supplier may require licenses to
manufacture such components if such processes are not owned by the
supplier or in the public domain and we may be unable to transfer
or sublicense the intellectual property rights we may have or later
obtain with respect to such activities.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
All entities involved in the preparation of therapeutics for
clinical trials or commercial sale, including our existing contract
manufacturers for Oncoprex, are subject to extensive regulation.
Components of a finished therapeutic product approved for
commercial sale or used in late-stage clinical trials must be
manufactured in accordance with cGMP. These regulations govern
manufacturing processes and procedures (including record keeping)
and the implementation and operation of quality systems to control
and assure the quality of investigational products and products
approved for sale. Poor control of production processes can lead to
the introduction of contaminants, or to inadvertent changes in the
properties or stability of our current and potential product
candidates that may not be detectable in final product testing. We
or our contract manufacturers must supply all necessary
documentation in support of a BLA on a timely basis and must adhere
to the FDA’s good laboratory practices, or GLP, and cGMP
regulations enforced by the FDA through its facilities inspection
program. Our facilities and quality systems and the facilities and
quality systems of some or all of our third-party contractors must
pass a pre-approval inspection for compliance with the applicable
regulations as a condition of regulatory approval of our current
and potential product candidates or any of our other potential
products. In addition, the regulatory authorities may, at any time,
audit or inspect a manufacturing facility involved with the
preparation of our current and potential product candidates or our
other potential products or the associated quality systems for
compliance with the regulations applicable to the activities being
conducted. If these facilities do not pass a pre-approval plant
inspection, FDA approval of the products may not be granted.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The regulatory authorities also may, at any time following approval
of a product for sale, audit our manufacturing facilities or those
of our third-party contractors. If any such inspection or audit
identifies a failure to comply with applicable regulations or if a
violation of our product specifications or applicable regulations
occurs independent of such an inspection or audit, we or the
relevant regulatory authority may require remedial measures that
may be costly and/or time-consuming for us or a third party to
implement and that may include the temporary or permanent
suspension of a clinical trial or commercial sales or the temporary
or permanent closure of a facility. Any such remedial measures
imposed upon us or third parties with whom we contract could
materially harm our business.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we or any of our third-party manufacturers fail to maintain
regulatory compliance, the FDA can impose regulatory sanctions
including, among other things, refusal to approve a pending
application for a new drug product or biologic product or
revocation of a pre-existing approval. As a result, our business,
financial condition and results of operations may be materially
harmed.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Additionally, if supply from one approved manufacturer is
interrupted, there could be a significant disruption in commercial
supply. An alternative manufacturer would need to be qualified
through a BLA supplement which could result in further delay. The
regulatory agencies may also require additional studies if a new
manufacturer is relied upon for commercial production. Switching
manufacturers may involve substantial costs and is likely to result
in a delay in our desired clinical and commercial timelines.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
These factors could cause the delay of clinical trials, regulatory
submissions, required approvals or commercialization of our current
and potential product candidates, cause us to incur higher costs
and prevent us from commercializing our products successfully.
Furthermore, if our suppliers fail to meet contractual
requirements, and we are unable to secure one or more replacement
suppliers capable of production at a substantially equivalent cost,
our clinical trials may be delayed or we could lose potential
revenue.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
33</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU34" id=
"_AEIOULastRenderedPageBreakAEIOU34"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If
we fail to comply with environmental,</font> <font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material
adverse effect on the success of our business.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may become subject to federal, state and local laws and
regulations governing the use, manufacture, storage, handling and
disposal of hazardous materials and certain waste products,
including numerous environmental, health and safety laws and
regulations, such as those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous
materials and wastes. Our operations may in the future involve the
use of hazardous materials, including chemicals and biological
materials. Our operations may also produce hazardous waste
products. We generally contract with third parties for the disposal
of these materials and wastes. We cannot eliminate the risk of
contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous
materials, we could be held liable for any resulting damages, and
any liability could exceed our resources. We also could incur
significant costs associated with civil or criminal fines and
penalties. In addition, we may incur substantial costs in order to
comply with current or future environmental, health and safety laws
and regulations. These current or future laws and regulations may
impair our research, development or production efforts. Failure to
comply with these laws and regulations also may result in
substantial fines, penalties or other sanctions.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Risks Related to Our Dependence on Third Parties</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may not be successful in establishing and maintaining
development and commercialization collaborations, which could
adversely affect our ability to develop certain of our current and
potential product candidates and our financial condition and
operating results.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Because developing pharmaceutical products, conducting clinical
trials, obtaining regulatory approval, establishing manufacturing
capabilities and marketing approved products are expensive, we may
enter into collaborations with companies that have the required
expertise. Additionally, if any of our current and potential
product candidates receives marketing approval, we may enter into
sales and marketing arrangements with third parties. If we are
unable to enter into arrangements on acceptable terms, if at all,
we may be unable to effectively market and sell our products in our
target markets. We expect to face competition in seeking
appropriate collaborators. Moreover, collaboration arrangements are
complex and time consuming to negotiate, document and implement and
they may require substantial resources to maintain. We may not be
successful in our efforts to establish and implement collaborations
or other alternative arrangements for the development of our
current and potential product candidates.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
When we collaborate with a third party for development and
commercialization of a product candidate, we can expect to
relinquish some or all of the control over the future success of
that product candidate to the third party.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
One or more of our collaboration partners may not devote sufficient
resources to the commercialization of our current and potential
product candidates or may otherwise fail in their
commercialization. The terms of any collaboration or other
arrangement that we establish may contain provisions that are not
favorable to us. In addition, any collaboration that we enter into
may be unsuccessful in the development and commercialization of our
current and potential product candidates. In some cases, we may be
responsible for continuing preclinical and initial clinical
development of a product candidate or research program under a
collaboration arrangement, and the payment we receive from our
collaboration partner may be insufficient to cover the cost of this
development. If we are unable to reach agreements with suitable
collaborators for our current and potential product candidates, we
would face increased costs, we may be forced to limit the number of
our current and potential product candidates we can commercially
develop or the territories in which we commercialize them. As a
result, we might fail to commercialize products or programs for
which a suitable collaborator cannot be found. If we fail to
achieve successful collaborations, our operating results and
financial condition could be materially and adversely affected.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We rely, and expect to continue to rely, on third parties to
conduct, supervise and monitor our clinical trials, and if these
third parties perform in an unsatisfactory manner, it may harm our
business.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We rely on CROs and clinical trial sites to ensure our clinical
trials are conducted properly and on time. While we have agreements
governing their activities, we may have limited influence over
their actual performance. We control only certain aspects of our
CROs’ activities. Nevertheless, we are responsible for ensuring
that each of our clinical trials is conducted in accordance with
the applicable protocol, legal, regulatory and scientific
standards, and our reliance on the CROs does not relieve us of our
regulatory responsibilities.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU35" id=
"_AEIOULastRenderedPageBreakAEIOU35"></a>We and our CROs are
required to comply with the GCPs for conducting, recording and
reporting the results of clinical trials to assure that the data
and reported results are credible and accurate and that the rights,
integrity and confidentiality of clinical trial participants are
protected. The FDA enforces these GCPs through periodic inspections
of study sponsors, principal investigators and clinical trial
sites. If we or our CROs fail to comply with applicable GCPs, the
clinical data generated in our future clinical trials may be deemed
unreliable, and the FDA may require us to perform additional
clinical trials before approving any marketing applications. Upon
inspection, the FDA may determine that our clinical trials did not
comply with GCPs. In addition, our ongoing and future clinical
trials will require a sufficient number of test subjects to
evaluate the safety and effectiveness of our current and
potential</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
34</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
produc</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t
candidates. Accordingly, if our CROs fail to comply with these
regulations or fail to recruit a sufficient number of patients, we
may be required to repeat such clinical trials, which would delay
the regulatory approval process.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our CROs are not our employees, and we are not able to directly
monitor whether or not they devote sufficient time and resources to
our clinical and nonclinical programs. These CROs may also have
relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials
or other drug development activities that could harm our
competitive position. If our CROs do not successfully carry out
their contractual duties or obligations, fail to meet expected
deadlines, or if the quality or accuracy of the clinical data they
obtain is compromised due to their failure to adhere to our
clinical protocols or regulatory requirements, or for any other
reasons, our clinical trials may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval
for or successfully commercialize our current and potential product
candidates. As a result, our financial results and the commercial
prospects for our current and potential product candidates would be
harmed, our costs could increase and our ability to generate
revenues could be delayed.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We rely, and expect to continue to rely, on third parties to
distribute, manufacture and perform release testing for our current
and potential product candidates and other key materials and if
such third parties do not carry out their contractual duties or
meet expected deadlines, we may not be able to obtain regulatory
approvals for our current and potential product candidates.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We intend to continue to rely on third-party contract manufacturing
organizations, or CMOs, to produce our current and potential
product candidates and other key materials and on third-party
contract testing organizations, or CTOs, for the establishment and
performance of validated product release assays, but we have not
entered into binding agreements with any such CMOs or CTOs to
support commercialization. Additionally, any CMO may not have
experience producing our current and potential product candidates
at commercial levels and may not achieve the necessary regulatory
approvals or produce our products at the quality, quantities,
locations and timing needed to support commercialization. We may
change our manufacturing process, and there can be no guarantee
that the regulatory authorities will approve any new process in a
timely manner or ever. Also, as a consequence of the manufacturing
change, there may be a requirement to do more preclinical safety or
efficacy studies, develop new manufacturing and release assays
and/or repeat all or part of the ascending dose safety study in
animals or humans. Regulatory requirements ultimately imposed could
adversely affect our ability to test, manufacture or market
products.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Although we intend to rely on third-party manufacturers for
commercialization, we currently utilize a sole source manufacturer
to support our clinical trials. We may be unable to negotiate
binding agreements with this manufacturer or additional
manufacturers to support our commercialization activities at
commercially reasonable terms.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
No manufacturer we know of currently has the experience or ability
to produce our current and potential product candidates at
reasonable commercial levels or under full commercial requirements.
We may encounter technical or scientific issues related to
manufacturing or development that we may be unable to resolve in a
timely manner or with available funds. Further, we have not
completed the characterization and validation activities necessary
for commercial and regulatory approvals. If our manufacturing and
testing partners do not obtain such regulatory approvals, our
commercialization efforts may be harmed.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Even if we timely develop a manufacturing process for Oncoprex and
successfully transfer it to third-party manufacturers, if such
third-party manufacturers are unable to produce our current and
potential product candidates in the necessary quantities, or in
compliance with current Good Manufacturing Practices, or cGMP, or
in compliance with pertinent regulatory requirements, and within
our planned time frame and cost parameters, the development and
sales of our products, if approved, may be materially harmed. The
facilities used by our contract manufacturers to manufacture our
current and potential product candidates must be approved by the
FDA pursuant to inspections that will be conducted after we submit
our BLA to the FDA. We do not control the manufacturing process of,
and are completely dependent on, our contract manufacturing
partners for compliance with cGMPs for the manufacture of our
current and potential product candidates. If our contract
manufacturers cannot successfully manufacture material that
conforms to our specifications and the strict regulatory
requirements of the FDA or others, they will not be able to secure
and/or maintain regulatory approval for their manufacturing
facilities. In addition, we have no control over the ability of our
contract manufacturers to maintain adequate quality control,
quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these
facilities for the manufacture of our current and potential product
candidates or if it withdraws any such approval in the future, we
may need to find alternative manufacturing facilities, which would
significantly affect our ability to develop, obtain regulatory
approval for or market our current and potential product
candidates, if approved. In addition, any failure to achieve and
maintain compliance with these laws, regulations and standards
could subject us to the risk that we may have to suspend the
manufacturing of our current and potential product candidates or
that obtained approvals could be revoked, which would adversely
affect our business and reputation.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU36" id=
"_AEIOULastRenderedPageBreakAEIOU36"></a>In addition, any
significant disruption in our supplier relationships could harm our
business. We source key materials, devices and equipment from third
parties, either directly through agreements with suppliers or
indirectly through our manufacturers who have agreements with
suppliers. There is a small number of suppliers for certain key
materials and components that are used to manufacture our current
and potential product candidates. Such suppliers may not sell these
key materials to our manufacturers at the times or</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
35</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
quantities we need them or on commercially reasonable terms. We may
not have any co</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ntrol
over the process or timing of the acquisition of these key
materials by our manufacturers.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We also expect to rely on other third parties to store and
distribute our products for our clinical trials. Any performance
failure on the part of our distributors could delay clinical
development or marketing approval of our current and potential
product candidates or commercialization of our products, if
approved, producing additional losses and depriving us of potential
product revenue.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We have completed and may in the future complete related party
transactions that were not and may not be conducted on an arm’s
length basis.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our leading drug candidate, Oncoprex, is based upon patents and
related technology covered by a patent and technology license
agreement between The University of Texas MD Anderson Cancer
Center, or MD Anderson, and Introgen Therapeutics, Inc. (such
technology license agreement is referred to as the “MD Anderson
License Agreement”), under which we have rights to patents covering
use of various genes, including the TUSC2 gene, for treatment of
cancer, as well as know-how and related intellectual property. In
2007, the MD Anderson License Agreement was sublicensed by Introgen
Therapeutics, Inc. to Introgen Research Institute, Inc., a Texas
corporation (IRI) and in 2009 this sublicense was assigned by IRI
to us, and we granted back to IRI a nonexclusive, royalty-free
license to use and practice the licensed technology for
non-commercial research purposes. As consideration for this
assignment, we agreed to assume all of IRI’s obligations to MD
Anderson under the MD Anderson License Agreement, including ongoing
patent related expenses and royalty obligations. IRI also agreed in
2011 to provide additional technology licensing opportunities and
services to us in return for monthly payments and our obligation to
pay to IRI a royalty of one percent (1%) on sales of products
licensed to us under the MD Anderson License Agreement. We also
granted a non-exclusive, royalty-free sublicense to IRI in 2011 for
non-commercial research purposes. IRI’s obligations to provide
additional technology licensing opportunities and services to us,
and our obligation to make monthly payments to IRI, were terminated
in 2012; however, our obligation to pay the one percent (1%)
royalty to IRI upon sales of products licensed to us under the MD
Anderson License Agreement is ongoing. This royalty obligation
continues for 21 years after the later of the termination of the MD
Anderson License Agreement and the termination of the sublicense
assigned by IRI to us. IRI is controlled by Rodney Varner and his
immediate family members. Mr. Varner is currently Chairman of our
board of directors, having joined our board of directors on August
15, 2012, and has been our President and Chief Executive Officer
since August 29, 2012; accordingly, in 2009 and 2011, when the
above referenced agreements between IRI and Genprex were entered
into, Mr. Varner was neither a member of our board of directors nor
an executive officer of Genprex. When the 2011 agreement was
entered into, Mr. Varner was deemed to be an “affiliate of the
Company due to his beneficial ownership of approximately 39% of our
issued and outstanding shares. Although we believe that these
transactions were conducted on an arm’s length basis, it is
possible that the terms were less favorable to us than they might
have been in a transaction with an unrelated party. We have adopted
a written related-person transactions policy that sets forth our
policies and procedures regarding the identification, review,
consideration and oversight of related-person transactions.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Risks Related to Our Intellectual Property</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
If we fail to obtain or protect our intellectual property, our
business will be impaired.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we are unable to obtain or protect intellectual property rights
related to our current and potential product candidates, we may not
be able to compete effectively in our markets. Third party claims
of intellectual property infringement may prevent or delay our
development and commercialization efforts. We may not be successful
in obtaining or maintaining necessary rights to product components
and processes for our development pipeline through acquisitions and
end licenses.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we fail to comply with our obligations in the agreements under
which we license intellectual property rights from third parties or
otherwise experience disruptions to our business relationships with
our licensors, we could lose license rights that are important to
our business. We may be involved in lawsuits to protect or enforce
our patents or the patents or our licensors, which could be
expensive, time-consuming, and/or unsuccessful.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Obtaining and maintaining patent protection depends upon compliance
with various procedural, document submission, fee payment, and
other requirements imposed by governmental patent agencies, and our
patent protection could be reduced or eliminated for noncompliance
with these requirements. Issued patents covering our current and
potential product candidates could be found invalid or
unenforceable if challenged in court, or could expire before we
obtain product approval. The scope of our issued patents could be
found to be narrower and provide less protection than we
anticipate.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
36</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU37" id=
"_AEIOULastRenderedPageBreakAEIOU37"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If
we fail to comply with our obligations in the agreements
unde</font><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r
which we license intellectual property rights from MD Anderson, or
otherwise experience disruptions to our business relationships with
MD Anderson or other future licensors, we could lose license rights
that are important to our business.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Under our license agreement with MD Anderson, we hold a worldwide,
exclusive license to, among other things, manufacture and market
products utilizing certain inventions that are critical to our
business. We expect to enter into additional license agreements in
the future. Our existing license agreement imposes various
diligence, royalty and other obligations on us, and we expect that
future license agreements will impose various diligence, milestone
payment, royalty and other obligations on us. If we fail to comply
with our obligations under these agreements, or we are subject to a
bankruptcy, the licensor may have the right to terminate the
license, in which event we would not be able to market products
covered by the license. See “Business—License and Collaboration
Agreements” for a description of our license agreements with MD
Anderson, which includes a description of the termination
provisions of these agreements.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may need to obtain licenses from third parties to advance our
research or allow commercialization of our current and potential
product candidates. We may fail to obtain any of these licenses at
a reasonable cost or on reasonable terms, if at all. In that event,
we may be required to expend significant time and resources to
develop or license replacement technology. If we are unable to do
so, we may be unable to develop or commercialize the affected
product candidates, which could harm our business significantly. We
cannot provide any assurances that third-party patents do not exist
which might be enforced against our current product candidates or
future products, resulting in either an injunction prohibiting our
sales, or, with respect to our sales, an obligation on our part to
pay royalties and/or other forms of compensation to third
parties.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In certain cases, patent prosecution of our licensed technology may
be controlled solely by the licensor. If our licensors fail to
obtain and maintain patent or other protection for the proprietary
intellectual property we license from them, we could lose our
rights to the intellectual property or our exclusivity with respect
to those rights, and our competitors could market competing
products using the intellectual property. In certain cases, we
control the prosecution of patents resulting from licensed
technology. In the event we breach any of our obligations related
to such prosecution, we may incur significant liability to our
licensing partners. Licensing of intellectual property is of
critical importance to our business and involves complex legal,
business and scientific issues and is complicated by the rapid pace
of scientific discovery in our industry. Disputes may arise
regarding intellectual property subject to a licensing agreement,
including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the scope of rights
granted under the license agreement and other
interpretation-related issues;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the extent to which our
technology and processes infringe intellectual property of the
licensor that is not subject to the licensing agreement;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the sublicensing of
patent and other rights under our collaborative development
relationships;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our diligence
obligations under the license agreement and what activities satisfy
those diligence obligations;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the ownership of
inventions and know-how resulting from the joint creation or use of
intellectual property by our licensors and us and our partners;
and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the priority of
invention of patented technology.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If disputes over intellectual property that we have licensed
prevent or impair our ability to maintain our current licensing
arrangements on acceptable terms, we may be unable to successfully
develop and commercialize the affected product candidates.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
The intellectual property rights we have licensed from MD Anderson
are subject to the rights of the U.S. government.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU38" id=
"_AEIOULastRenderedPageBreakAEIOU38"></a>The rights we have
obtained pursuant to our license agreement with MD Anderson are
made subject to the rights of the U.S. government to the extent
that the technology covered by the licensed intellectual property
was developed under a funding agreement between MD Anderson and the
U.S. government. Additionally, to the extent there is any conflict
between our license agreement with MD Anderson and applicable laws
or regulations, applicable laws and regulations will prevail.
Similarly, to the extent there is any conflict between our license
agreement with MD Anderson and MD Anderson’s funding agreement with
the US government, the terms of the funding agreement will prevail.
Some, and possibly all, of our licensed intellectual property
rights from MD Anderson have been developed in the course of
research funded by the U.S. government. As a result, the U.S.
government may have certain rights to intellectual property
embodied in our current or future products pursuant to the
Bayh-Dole Act of 1980. Government rights in certain inventions
developed under a government-funded program include a
non-exclusive, non-transferable, irrevocable worldwide license to
use inventions for any governmental purpose. In addition, the U.S.
government has the right to require us, or an assignee or exclusive
licensee to such inventions, to grant licenses to any of these
inventions to a third party if the U.S. government determines that
adequate steps have not been taken to commercialize the invention,
that government action is necessary to meet public health or safety
needs, that government action is necessary to meet requirements for
public use under federal regulations, or that the right to use or
sell such inventions is exclusively licensed to an entity within
the U.S. and substantially manufactured outside the U.S. without
the</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
37</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
U.S. governme</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt’
s prior approval. Additionally, we may be restricted from granting
exclusive licenses for the right to use or sell our inventions
created pursuant to such agreements unless the licensee agrees to
additional restrictions (e.g., manufacturing
substantiall</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y
all of the invention in the U.S.). The U.S. government also has the
right to take title to these inventions if we fail to disclose the
invention to the government and fail to file an application to
register the intellectual property within specified time</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
limits. In addition, the U.S. government may acquire title in any
country in which a patent application is not filed within specified
time limits. Additionally, certain inventions are subject to
transfer restrictions during the term of these agreements
an</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d
for a period thereafter, including sales of products or components,
transfers to foreign subsidiaries for the purpose of the relevant
agreements, and transfers to certain foreign third parties. If any
of our intellectual property becomes subject to any
o</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f
the rights or remedies available to the U.S. government or third
parties pursuant to the Bayh-Dole Act of 1980, this could impair
the value of our intellectual property and could adversely affect
our business. The U.S. government has not exercised any of</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
these rights or provided us with any notice of its intent to
exercise any of these rights with respect to any of the
intellectual property licensed to us by MD Anderson. We are not
aware of any instance in which the U.S. government has ever
exercised any</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
such rights with respect to any technologies or other intellectual
property developed under funding agreements with the U.S.
government.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
If we are unable to protect our intellectual property rights or if
our intellectual property rights are inadequate for our technology
and product candidates, our competitive position could be
harmed.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our commercial success will depend in part on our ability and the
ability of our licensors to obtain and maintain patent and other
intellectual property protection in the United States and other
countries with respect to our proprietary technology and products.
We rely on trade secret, patent, copyright and trademark laws, and
confidentiality, licensing and other agreements with employees and
third parties, all of which offer only limited protection. We seek
to protect our proprietary position by filing and prosecuting
patent applications in the United States and abroad related to our
novel technologies and products that are important to our
business.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The patent positions of biotechnology and pharmaceutical companies
generally are highly uncertain, involve complex legal and factual
questions and have in recent years been the subject of much
litigation. As a result, the issuance, scope, validity,
enforceability and commercial value of our patents, including those
patent rights licensed to us by third parties, are highly
uncertain. The steps we or our licensors have taken to protect our
proprietary rights may not be adequate to preclude misappropriation
of our proprietary information or infringement of our intellectual
property rights, both inside and outside of the United States.
Further, the examination process may require us or our licensors to
narrow the claims for our pending patent applications, which may
limit the scope of patent protection that may be obtained if these
applications issue. The rights already granted under any of our
currently issued patents or those licensed to us and those that may
be granted under future issued patents may not provide us with the
proprietary protection or competitive advantages we are seeking. If
we or our licensors are unable to obtain and maintain patent
protection for our technology and products, or if the scope of the
patent protection obtained is not sufficient, our competitors could
develop and commercialize technology and products similar or
superior to ours, and our ability to successfully commercialize our
technology and products may be adversely affected. It is also
possible that we or our licensors will fail to identify patentable
aspects of inventions made in the course of our development and
commercialization activities before it is too late to obtain patent
protection on them. It is also possible that as research and
development progresses, the direction of our intellectual property
strategy and patent portfolio will change, resulting in strategic
business decisions to allow certain patents or patent applications
to be abandoned or lapse.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
With respect to patent rights, we do not know whether any of the
pending patent applications relating to any of our current and
potential product candidates will result in the issuance of patents
that effectively protect our technology or products, or if any of
our licensors’ issued patents will effectively prevent others from
commercializing competitive technologies and products. Publications
of discoveries in the scientific literature often lag behind the
actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18 months
after filing or in some cases not at all, until they are issued as
a patent. Therefore, we cannot be certain that we or our licensors
were the first to make the inventions claimed in our owned or
licensed patents or pending patent applications, or that we or our
licensors were the first to file for patent protection of such
inventions.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our pending applications cannot be enforced against third parties
practicing the technology claimed in such applications unless and
until a patent issues from such applications. Because the issuance
of a patent is not conclusive as to its inventorship, scope,
validity or enforceability, issued patents that we have licensed
from third parties may be challenged in the courts or patent
offices in the United States and abroad. Such challenges may result
in the loss of patent protection, the narrowing of claims in such
patents or the invalidity or unenforceability of such patents,
which could limit our ability to stop others from using or
commercializing similar or identical technology and products, or
limit the duration of the patent protection for our technology and
products. Protecting against the unauthorized use of our or our
licensor’s patented technology, trademarks and other intellectual
property rights is expensive, difficult and may in some cases not
be possible. In some cases, it may be difficult or impossible to
detect third-party infringement or misappropriation of our
intellectual property rights, even in relation to issued patent
claims, and proving any such infringement may be even more
difficult.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
38</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU39" id=
"_AEIOULastRenderedPageBreakAEIOU39"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-party
claims of intellectual property infringement may prevent or delay
our development and commercialization efforts.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our commercial success depends in part on our avoiding infringement
of the patents and proprietary rights of third parties. There is a
substantial amount of litigation, both within and outside the
United States, involving patent and other intellectual property
rights in the biotechnology and pharmaceutical industries,
including patent infringement lawsuits, interferences, oppositions
and <font style="font-style:italic;">inter partes</font>
reexamination proceedings before the US Patent and Trademark
Office, or US PTO, and corresponding foreign patent offices.
Numerous US and foreign issued patents and pending patent
applications, which are owned by third parties, exist in the fields
in which we are pursuing development candidates. As the
biotechnology and pharmaceutical industries expand and more patents
are issued, the risk increases that our current and potential
product candidates may be subject to claims of infringement of the
patent rights of third parties.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Third parties may in the future assert that we are employing their
proprietary technology without authorization. There may be
third-party patents or patent applications with claims to
materials, formulations, methods of manufacture or methods for
treatment related to the use or manufacture of our current and
potential product candidates. Because patent applications can take
many years to issue, there may be currently pending patent
applications which may later result in issued patents that our
current and potential product candidates may infringe. In addition,
third parties may obtain patents in the future and claim that use
of our technologies infringes upon these patents. If any
third-party patents were held by a court of competent jurisdiction
to cover the manufacturing process of any of our current and
potential product candidates, or any final product itself, the
holders of any such patents may be able to block our ability to
commercialize such product candidate unless we obtained a license
under the applicable patents, or until such patents expire.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Similarly, if any third-party patents were held by a court of
competent jurisdiction to cover aspects of our formulations,
processes for manufacture or methods of use, including combination
therapy, the holders of any such patents may be able to block our
ability to develop and commercialize the applicable product
candidate unless we obtained a license or until such patent
expires. In either case, such a license may not be available on
commercially reasonable terms or at all.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Parties making claims against us may obtain injunctive or other
equitable relief, which could effectively block our ability to
further develop and commercialize one or more of our current and
potential product candidates. Defense of these claims, regardless
of their merit, may involve substantial litigation expense and
would be a substantial diversion of employee resources from our
business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including
treble damages and attorneys’ fees for willful infringement, pay
royalties, redesign our infringing products or obtain one or more
licenses from third parties, which may be impossible or require
substantial time and monetary expenditure.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may not be successful in obtaining or maintaining necessary
rights to product components and processes for our development
pipeline through acquisitions and in-licenses.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Presently we believe that we have rights to the intellectual
property, through licenses from third parties and under patents
that we own, to develop our current and potential product
candidates. Because our programs may involve additional product
candidates that may require the use of proprietary rights held by
third parties, the growth of our business may depend in part on our
ability to acquire, in-license or use these proprietary rights. In
addition, our current and potential product candidates may require
specific formulations to work effectively and efficiently and these
rights may be held by others. We may be unable to acquire or
in-license any compositions, methods of use, processes or other
third-party intellectual property rights from third parties that we
identify. The licensing and acquisition of third-party intellectual
property rights is a competitive area, and a number of more
established companies are also pursuing strategies to license or
acquire third-party intellectual property rights that we may
consider attractive. These established companies may have a
competitive advantage over us due to their size, cash resources and
greater clinical development and commercialization
capabilities.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, companies that perceive us to be a competitor may be
unwilling to assign or license rights to us. We also may be unable
to license or acquire third-party intellectual property rights on
terms that would allow us to make an appropriate return on our
investment. If we are unable to successfully obtain rights to
required third-party intellectual property rights, our business,
financial condition and prospects for growth could suffer.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may incur substantial costs as a result of litigation or other
proceedings relating to patent and other intellectual property
rights.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU40" id=
"_AEIOULastRenderedPageBreakAEIOU40"></a>We may from time to time
seek to enforce our intellectual property rights against infringers
when we determine that a successful outcome is probable and may
lead to an increase in the value of the intellectual property. If
we choose to enforce our patent rights against a party, then that
individual or company has the right to ask the court to rule that
such patents are invalid or should not be enforced. Additionally,
the validity of our patents and the patents we have licensed may be
challenged if a petition for post grant proceedings such as
<font style="font-style:italic;">inter partes</font> review and
post grant review is filed within the statutorily applicable time
with the US PTO. These lawsuits and proceedings are expensive and
would consume time and resources and divert the attention of
managerial and scientific personnel even if we were successful in
stopping the infringement of such patents. In addition, there is a
risk that the court will decide that such patents are not valid and
that we do not have the right to stop the other party from using
the inventions. There is also the risk</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
39</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
that, even if the validity of such patents is upheld, the court
will refuse to stop the other party on the ground that such other
party’s activities do not infringe our intellectual property
rights. In addition, in rece</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt
years the U.S. Supreme Court modified some tests used by the US PTO
in granting patents over the past 20 years, which may decrease the
likelihood that we will be able to obtain patents and increase the
likelihood of a challenge of any patents we obtain</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
or license.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
If we are not able to adequately prevent disclosure of trade
secrets and other proprietary information, the value of our
technology and products could be significantly diminished.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We rely on trade secrets to protect our proprietary technologies,
especially where we do not believe patent protection is appropriate
or obtainable. However, trade secrets are difficult to protect. We
rely in part on confidentiality agreements with our employees,
consultants, outside scientific collaborators, sponsored
researchers and other advisors to protect our trade secrets and
other proprietary information. These agreements may not effectively
prevent disclosure of confidential information and may not provide
an adequate remedy in the event of unauthorized disclosure of
confidential information. In addition, others may independently
discover our trade secrets and proprietary information. Costly and
time-consuming litigation could be necessary to enforce and
determine the scope of our proprietary rights, and failure to
obtain or maintain trade secret protection could adversely affect
our competitive business position.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Our reliance on third parties may require us to share our trade
secrets, which increases the possibility that a competitor will
discover them or that our trade secrets will be misappropriated or
disclosed.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Because we rely on third parties to manufacture our current and
potential product candidates, and because we collaborate with
various organizations and academic institutions on the advancement
of our current and potential product candidates, we must, at times,
share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and,
if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with
our manufacturers, collaborators, advisors, employees and
consultants prior to beginning research or disclosing proprietary
information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information, such
as trade secrets. Despite the contractual provisions employed when
working with third parties, the need to share trade secrets and
other confidential information increases the risk that such trade
secrets become known by our competitors, are inadvertently
incorporated into the technology of others, are used
inappropriately to create new inventions or are disclosed or used
in violation of these agreements. Given that our proprietary
position is based, in part, on our know-how and trade secrets, a
competitor’s discovery of our trade secrets or other unauthorized
use or disclosure would impair our competitive position and may
have a material adverse effect on our business.&nbsp;&nbsp;</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, these agreements typically restrict the ability of our
collaborators, advisors, employees and consultants to publish data
potentially relating to our trade secrets. Our academic
collaborators typically have rights to publish data, provided that
we are notified in advance and may delay publication for a
specified time in order to secure our intellectual property rights
arising from the collaboration. In other cases, publication rights
are controlled exclusively by us, although in some cases we may
share these rights with other parties. We may also conduct joint
research and development programs that may require us to share
trade secrets under the terms of research and development
partnerships or similar agreements. Despite our efforts to protect
our trade secrets, our competitors may discover our trade secrets
through breach of these agreements, independent development or
publication of information including our trade secrets in cases
where we do not have proprietary or otherwise protected rights at
the time of publication. A competitor’s discovery of our trade
secrets may impair our competitive position and have an adverse
impact on our business.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may be involved in lawsuits to protect or enforce our patents or
the patents of our licensors, which could be expensive,
time-consuming and unsuccessful.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Competitors may infringe our patents or the patents of our
licensors. To counter infringement or unauthorized use, we may be
required to file infringement claims, which can be expensive and
time-consuming. In addition, in an infringement proceeding, a court
may decide that a patent of ours or our licensors is not valid, is
unenforceable and/or is not infringed, or may refuse to stop the
other party from using the technology at issue on the grounds that
our patents do not cover the technology in question. An adverse
result in any litigation or defense proceedings could put one or
more of our patents at risk of being invalidated or interpreted
narrowly and could put our patent applications at risk of not
issuing.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Interference proceedings provoked by third parties or brought by us
may be necessary to determine the priority of inventions with
respect to our patents or patent applications or those of our
licensors. An unfavorable outcome could require us to cease using
the related technology or to attempt to license rights to it from
the prevailing party. Our business could be harmed if the
prevailing party does not offer us a license on commercially
reasonable terms. Our defense of litigation or interference
proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees.
We may not be able to prevent, alone or with our licensors,
misappropriation of our intellectual property rights, particularly
in countries where the laws may not protect those rights as fully
as in the United States.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
40</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU41" id=
"_AEIOULastRenderedPageBreakAEIOU41"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,
because of the substantial amount of discovery required in
connection with intellectual property litigation, there is a risk
that some of our confidential information could be compromised by
disclosure during</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
this type of litigation. There could also be public announcements
of the results of hearings, motions or other interim proceedings or
developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
effect on the price of our common stock.</font></p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Obtaining and maintaining our patent protection depends on
compliance with various procedural, document submission, fee
payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated
for non-compliance with these requirements.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Periodic maintenance fees, renewal fees, annuity fees and various
other governmental fees on patents and/or applications will be due
to be paid to the US PTO and various governmental patent agencies
outside of the United States in several stages over the lifetime of
the patents and/or applications. We employ an outside firm and rely
on our outside counsel to pay these fees due to non-US patent
agencies. The US PTO and various non-US governmental patent
agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the
patent application process. We employ reputable law firms and other
professionals to help us comply, and in many cases, an inadvertent
lapse can be cured by payment of a late fee or by other means in
accordance with the applicable rules. However, there are situations
in which non-compliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss
of patent rights in the relevant jurisdiction. In such an event,
our competitors might be able to enter the market and this
circumstance would have a material adverse effect on our
business.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Issued patents covering our current and potential product
candidates could be found invalid or unenforceable if challenged in
court.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If we, MD Anderson or one of our future licensing partners
initiated legal proceedings against a third party to enforce a
patent covering one of our current and potential product
candidates, the defendant could counterclaim that the patent
covering our product candidate is invalid and/or unenforceable. In
patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to
meet any of several statutory requirements, including lack of
novelty, obviousness or non-enablement. Grounds for an
unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant
information from the US PTO, or made a misleading statement, during
prosecution. Third parties may also raise similar claims before
administrative bodies in the United States or abroad, even outside
the context of litigation. Such mechanisms include re-examination,
post grant review and equivalent proceedings in foreign
jurisdictions (e.g., opposition proceedings). Such proceedings
could result in revocation or amendment to our patents in such a
way that they no longer cover our current and potential product
candidates. The outcome following legal assertions of invalidity
and unenforceability is unpredictable. With respect to the validity
question, for example, we cannot be certain that there is no
invalidating prior art, of which we and the patent examiner were
unaware during prosecution. If a defendant were to prevail on a
legal assertion of invalidity and/or unenforceability, we would
lose at least part, and perhaps all, of the patent protection on
our current and potential product candidates. Such a loss of patent
protection would have a material adverse impact on our
business.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may be subject to claims that our employees, consultants or
independent contractors have wrongfully used or disclosed
confidential information of third parties or that our employees
have wrongfully used or disclosed alleged trade secrets of their
former employers.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may in the future employ individuals who were previously
employed at universities or other biotechnology or pharmaceutical
companies, including our competitors or potential competitors.
Although we try to ensure that our employees, consultants and
independent contractors do not use the proprietary information or
know-how of others in their work for us, we may be subject to
claims that we or our employees, consultants or independent
contractors have inadvertently or otherwise used or disclosed
intellectual property, including trade secrets or other proprietary
information, of any of our employee’s former employer or other
third parties. Litigation may be necessary to defend against these
claims. If we fail in defending any such claims, in addition to
paying monetary damages, we may lose valuable intellectual property
rights or personnel, which could adversely impact our business.
Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction
to management and other employees.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may be subject to claims challenging the inventorship or
ownership of our patents and other intellectual property.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may be subject to claims that former employees, collaborators or
other third parties have an ownership interest in our patents or
other intellectual property. We may have potential ownership
disputes arising, for example, from conflicting obligations of
consultants, collaborators or others who are involved in developing
our current and potential product candidates. Litigation may be
necessary to defend against these and other claims challenging
inventorship or ownership. If we fail in defending any such claims,
in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or
right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on our business. Even if we are
successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and
other employees.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
41</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU42" id=
"_AEIOULastRenderedPageBreakAEIOU42"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes
in U.S. patent law could diminish th</font><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e
value of patents in general, thereby impairing our ability to
protect our products.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The United States has enacted and is currently implementing
wide-ranging patent reform legislation. Recent U.S. Supreme Court
rulings have narrowed the scope of patent protection available in
certain circumstances and weakened the rights of patent owners in
certain situations. In addition to increasing uncertainty with
regard to our ability to obtain patents in the future, this
combination of events has created uncertainty with respect to the
value of patents, once obtained. Depending on decisions by the U.S.
Congress, the federal courts and the U.S. PTO, the laws and
regulations governing patents could change in unpredictable ways
that would weaken our ability to obtain new patents or to enforce
our existing patents and patents that we might obtain in the
future.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We have not yet registered the trademark for Oncoprex, and failure
to secure such registration could adversely affect our
business.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
While we own pending trademark applications for the marks “GENPREX”
and “ONCOPREX”, these marks have not yet been approved by the U.S.
Patent and Trademark Office. During trademark registration
proceedings, we may receive rejections. Although we would be given
an opportunity to respond to those rejections, we may be unable to
overcome such rejections. In addition, in the US PTO and in
comparable agencies in many foreign jurisdictions, third parties
are given an opportunity to oppose pending trademark applications
and to seek to cancel registered trademarks. Opposition or
cancellation proceedings may be filed against our trademarks, and
our trademarks may not survive such proceedings. Moreover, any name
we propose to use with our current and potential product candidates
in the United States must be approved by the FDA, regardless of
whether we have registered it, or applied to register it, as a
trademark. The FDA typically conducts a review of proposed product
names, including an evaluation of potential for confusion with
other product names. If the FDA objects to any of our proposed
proprietary product names, we may be required to expend significant
additional resources in an effort to identify a suitable substitute
name that would qualify under applicable trademark laws, not
infringe the existing rights of third parties and be acceptable to
the FDA.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may not be able to protect our intellectual property rights
throughout the world.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Filing, prosecuting and defending patents on product candidates in
all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries
outside the United States can be less extensive than those in the
United States. In addition, the laws of some foreign countries do
not protect intellectual property rights to the same extent as
federal and state laws in the United States. Consequently, we may
not be able to prevent third parties from practicing our inventions
in all countries outside the United States, or from selling or
importing products made using our inventions in and into the United
States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to
develop their own products and further, may export otherwise
infringing products to territories where we have patent protection,
but enforcement is not as strong as that in the United States.
These products may compete with our products and our patents or
other intellectual property rights may not be effective or
sufficient to prevent them from competing.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Many companies have encountered significant problems in protecting
and defending intellectual property rights in foreign
jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of
patents, trade secrets and other intellectual property protection,
particularly those relating to biotechnology products, which could
make it difficult for us to stop the infringement of our patents or
marketing of competing products in violation of our proprietary
rights generally. Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial costs and divert
our efforts and attention from other aspects of our business, could
put our patents at risk of being invalidated or interpreted
narrowly and our patent applications at risk of not issuing and
could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate, and the damages or other
remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop
or license.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Risks Related to Employee Matters and Managing Growth</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We have no sales, marketing or distribution experience and we will
have to invest significant resources to develop those capabilities
or enter into acceptable third-party sales and marketing
arrangements.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We have no sales, marketing or distribution experience. To develop
sales, distribution and marketing capabilities, we will have to
invest significant amounts of financial and management resources,
some of which will need to be committed prior to any confirmation
that Oncoprex or any of our other potential product candidates will
be approved by the FDA. For product candidates for which we decide
to perform sales, marketing and distribution functions ourselves or
through third parties, we could face a number of additional risks,
including that we or our third-party sales collaborators may not be
able to build and maintain an effective marketing or sales force,
and we may experience difficulty in managing the growth of our
organization. If we use third parties to market and sell our
products, we may have limited or no control over their sales,
marketing and distribution activities on which our future revenues
may depend.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
42</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU43" id=
"_AEIOULastRenderedPageBreakAEIOU43"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We
will need to expand our operations and increase the size of our
company, and we may experience difficulties in</font> <font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
managing growth.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As of May 15, 2018, we had four full-time employees and one
part-time employee. As we advance our current and potential product
candidates through preclinical studies and clinical trials, we will
need to increase our product development, scientific and
administrative headcount to manage these programs. In addition, to
meet our obligations as a public company, we may need to increase
our general and administrative capabilities. Our management,
personnel and systems currently in place may not be adequate to
support this future growth. If we are unable to successfully manage
this growth and increased complexity of operations, our business
may be adversely affected.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may not be able to manage our business effectively if we are
unable to attract and retain key personnel and consultants.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may not be able to attract or retain qualified management,
finance, scientific and clinical personnel and consultants due to
the intense competition for qualified personnel and consultants
among biotechnology, pharmaceutical and other businesses. If we are
not able to attract and retain necessary personnel and consultants
to accomplish our business objectives, we may experience
constraints that will significantly impede the achievement of our
development objectives, our ability to raise additional capital and
our ability to implement our business strategy.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We are highly dependent on the development, regulatory,
commercialization and business development expertise of our
management team, key employees and consultants. Any of our
executive officers or key employees or consultants may terminate
their employment at any time. If we lose one or more of our
executive officers or key employees or consultants, our ability to
implement our business strategy successfully could be seriously
harmed. Replacing executive officers, key employees and consultants
may be difficult and may take an extended period of time because of
the limited number of individuals in our industry with the breadth
of skills and experience required to develop, gain regulatory
approval of and commercialize products successfully. Competition to
hire and retain employees and consultants from this limited pool is
intense, and we may be unable to hire, train, retain or motivate
these additional key personnel and consultants. Our failure to
retain key personnel or consultants could materially harm our
business.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, we have scientific and clinical advisors and
consultants who assist us in formulating our research, development
and clinical strategies. These advisors are not our employees and
may have commitments to, or consulting or advisory contracts with,
other entities that may limit their availability to us and
typically they will not enter into non-compete agreements with us.
If a conflict of interest arises between their work for us and
their work for another entity, we may lose their services. In
addition, our advisors may have arrangements with other companies
to assist those companies in developing products or technologies
that may compete with ours.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may use our financial and human resources to pursue a particular
research program or product candidate and fail to capitalize on
programs or product candidates that may be more profitable or for
which there is a greater likelihood of success.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Because we have limited resources, we may forego or delay pursuit
of opportunities with certain programs or product candidates or for
indications that later prove to have greater commercial potential.
Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and
development programs for product candidates may not yield any
commercially viable products. If we do not accurately evaluate the
commercial potential or target market for a particular product
candidate, we may relinquish valuable rights to that product
candidate through strategic collaboration, licensing or other
royalty arrangements in cases in which it would have been more
advantageous for us to retain sole development and
commercialization rights to such product candidate, or we may
allocate internal resources to a product candidate in a therapeutic
area in which it would have been more advantageous to enter into a
partnering arrangement.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
If we engage in future acquisitions or strategic partnerships, this
may increase our capital requirements, dilute our stockholders,
cause us to incur debt or assume contingent liabilities, and
subject us to other risks.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may evaluate and enter into various acquisitions and strategic
partnerships, including licensing or acquiring complementary
products, intellectual property rights, technologies, or
businesses. Any potential acquisition or strategic partnership may
entail numerous risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">increased operating
expenses and cash requirements;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the assumption of
additional indebtedness or contingent liabilities;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the issuance of our
equity securities;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">assimilation of
operations, intellectual property and products of an acquired
company, including difficulties associated with integrating new
personnel;</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
43</p>
<hr style="page-break-after:always;width:100%;" />
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<a name="_AEIOULastRenderedPageBreakAEIOU44" id=
"_AEIOULastRenderedPageBreakAEIOU44"></a><font style=
"font-family:Times New Roman;">the diversion of our management’s
attention from our existing product programs and initiatives in
purs</font><font style="font-family:Times New Roman;">uing such a
strategic merger or acquisition;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">retention of key
employees, the loss of key personnel, and uncertainties in our
ability to maintain key business relationships;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">risks and uncertainties
associated with the other party to such a transaction, including
the prospects of that party and their existing products or product
candidates and marketing approvals; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">our inability to
generate revenue from acquired technology and/or products
sufficient to meet our objectives in undertaking the acquisition or
even to offset the associated acquisition and maintenance
costs.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, if we undertake acquisitions, we may issue dilutive
securities, assume or incur debt obligations, incur large one-time
expenses and acquire intangible assets that could result in
significant future amortization expense. Moreover, we may not be
able to locate suitable acquisition opportunities and this
inability could impair our ability to grow or obtain access to
technology or products that may be important to the development of
our business.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Risks Related to Owning Our Common Stock</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
The market price of our common stock may be highly volatile, and
you may lose all or part of your investment.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The market price of our common stock is likely to be volatile. Our
stock price could be subject to wide fluctuations in response to a
variety of factors, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">adverse results or
delays in preclinical or clinical trials;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">reports of adverse
events in other gene therapy products or clinical trials of such
products;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">inability to obtain
additional funding;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">any delay in filing an
IND or BLA for any of our current and potential product candidates
and any adverse development or perceived adverse development with
respect to the FDA’s review of that IND or BLA;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">failure to develop
successfully and commercialize our current and potential product
candidates;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">failure to maintain our
existing strategic collaboration or enter into new
collaborations;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">failure by us or our
licensors and strategic collaboration partners to prosecute,
maintain or enforce our intellectual property rights;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">changes in laws or
regulations applicable to future products;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">inability to obtain
adequate product supply for our current and potential product
candidates or inability to do so at acceptable prices;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">adverse regulatory
decisions;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">introduction of new
products, services or technologies by our competitors;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">failure to meet or
exceed financial projections we may provide to the
public;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">failure to meet or
exceed the financial projections of the investment
community;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">the perception of the
pharmaceutical industry by the public, legislatures, regulators and
the investment community;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">announcements of
significant acquisitions, strategic partnerships, joint ventures or
capital commitments by us, our strategic collaboration partners or
our competitors;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">disputes or other
developments relating to proprietary rights, including patents,
litigation matters and our ability to obtain patent protection for
our technologies;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">additions or departures
of key scientific or management personnel;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">significant lawsuits,
including patent or stockholder litigation;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">changes in the market
valuations of similar companies;</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
44</p>
<hr style="page-break-after:always;width:100%;" />
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<a name="_AEIOULastRenderedPageBreakAEIOU45" id=
"_AEIOULastRenderedPageBreakAEIOU45"></a><font style=
"font-family:Times New Roman;">sales of our common stock by us or
our stockholders in the future; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">trading volume of our
common stock.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, companies trading in the stock market in general, and
The Nasdaq Capital Market in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of these companies.
Broad market and industry factors may negatively affect the market
price of our common stock, regardless of our actual operating
performance.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Nasdaq may delist our securities from its exchange, which could
limit investors’ ability to make transactions in our securities and
subject us to additional trading restrictions.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our common stock is listed on The Nasdaq Capital
Market.&nbsp;&nbsp;We cannot assure you that, in the future, our
securities will meet the continued listing requirements to be
listed on The Nasdaq Capital Market. If The Nasdaq Capital Market
delists our common stock, we could face significant material
adverse consequences, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">a limited availability
of market quotations for our securities;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">a determination that our
common stock is a “penny stock” which will require brokers trading
in our common stock to adhere to more stringent rules and possibly
resulting in a reduced level of trading activity in the secondary
trading market for our common stock;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">a limited amount of news
and analyst coverage for our company; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">a decreased ability to
issue additional securities or obtain additional financing in the
future.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Unstable market and economic conditions may have serious adverse
consequences on our business, financial condition and stock
price.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Global credit and financial markets have experienced extreme
volatility and disruptions in past years, including severely
diminished liquidity and credit availability, declines in consumer
confidence, declines in economic growth, increases in unemployment
rates and uncertainty about economic stability. We cannot assure
you that further deterioration in credit and financial markets and
confidence in economic conditions will not occur. Our general
business strategy may be adversely affected by any such economic
downturn, volatile business environment or continued unpredictable
and unstable market conditions. If the current equity and credit
markets deteriorate, or do not improve, it may make any necessary
debt or equity financing more difficult, more costly and more
dilutive. Failure to secure any necessary financing in a timely
manner and on favorable terms could have a material adverse effect
on our growth strategy, financial performance and stock price and
could require us to delay or abandon clinical development plans. In
addition, there is a risk that one or more of our current service
providers, manufacturers and other partners may not survive
difficult economic times, which could directly affect our ability
to attain our operating goals on schedule and on budget.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We have no intention of declaring dividends in the foreseeable
future.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The decision to pay cash dividends on our common stock rests with
our board of directors and will depend on our earnings,
unencumbered cash, capital requirements and financial condition. We
do not anticipate declaring any dividends in the foreseeable
future, as we intend to use any excess cash to fund our operations.
Investors in our common stock should not expect to receive dividend
income on their investment, and investors will be dependent on the
appreciation of our common stock to earn a return on their
investment.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We are an emerging growth company, and we cannot be certain if the
reduced reporting requirements applicable to emerging growth
companies will make our common stock less attractive to
investors.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We are an emerging growth company, as defined in the JOBS Act. For
as long as we continue to be an emerging growth company, we may
take advantage of exemptions from various reporting requirements
that are applicable to other public companies that are not emerging
growth companies, including not being required to comply with the
auditor attestation requirements of Section 404 of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements
and exemptions from the requirements of holding nonbinding advisory
votes on executive compensation and stockholder approval of any
golden parachute payments not previously approved. We could be an
emerging growth company for up to five years following the year in
which we completed the recently completed initial public offering
of our common stock, although circumstances could cause us to lose
that status earlier. We will remain an emerging growth company
until the earlier of (1) the last day of the fiscal year (a)
following the fifth anniversary of the completion of the recently
completed initial public offering of our common stock, (b) in which
we have total annual gross revenue of at least $1 billion or (c) in
which we are deemed to be a large accelerated filer, which requires
the market value of our common stock that is held by non-affiliates
to exceed $700 million as of the prior June 30th, and (2) the date
on which we have issued more than $1 billion in nonconvertible debt
during the prior three-year period.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
45</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU46" id=
"_AEIOULastRenderedPageBreakAEIOU46"></a><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even
after we no longer qualify as an emerging growth company, we may
still quali</font><font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fy
as a “smaller reporting company” which would allow us to take
advantage of many of the same exemptions from disclosure
requirements including not being required to comply with the
auditor attestation requirements of Section 404 of the
Sarbanes-Oxley Act</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
and reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements. We cannot predict if
investors will find our common stock less attractive because we may
rely on these exemptions. If some investors find our</font>
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
common stock less attractive as a result, there may be a less
active trading market for our common stock and our stock price may
be more volatile.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Under the JOBS Act, emerging growth companies can also delay
adopting new or revised accounting standards until such time as
those standards apply to private companies. We have irrevocably
elected not to avail ourselves of this exemption from new or
revised accounting standards and, therefore, will be subject to the
same new or revised accounting standards as other public companies
that are not emerging growth companies. As a result, changes in
rules of U.S. generally accepted accounting principles or their
interpretation, the adoption of new guidance or the application of
existing guidance to changes in our business could significantly
affect our financial position and results of operations.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We will incur significant increased costs as a result of operating
as a public company, and our management will be required to devote
substantial time to existing and new compliance initiatives.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As a public company, we will incur significant legal, accounting
and other expenses that we did not incur as a private company. We
will be subject to the reporting requirements of the Securities
Exchange Act of 1934, or the Exchange Act, which will require,
among other things, that we file with the Securities and Exchange
Commission, or the SEC, annual, quarterly and current reports with
respect to our business and financial condition. In addition, the
Sarbanes-Oxley Act, as well as rules subsequently adopted by the
SEC and The Nasdaq Capital Market to implement provisions of the
Sarbanes-Oxley Act, impose significant requirements on public
companies, including requiring establishment and maintenance of
effective disclosure and financial controls and changes in
corporate governance practices. Further, in July 2010, the
Dodd-Frank Wall Street Reform and Consumer Protection Act, or the
Dodd-Frank Act, was enacted. There are significant corporate
governance and executive compensation related provisions in the
Dodd-Frank Act that require the SEC to adopt additional rules and
regulations in these areas such as “say on pay” and proxy access.
Recent legislation permits emerging growth companies to implement
many of these requirements over a longer period and up to five
years from the pricing of the recently completed initial public
offering of our common stock. We intend to take advantage of this
new legislation but cannot guarantee that we will not be required
to implement these requirements sooner than budgeted or planned and
thereby incur unexpected expenses. Stockholder activism, the
current political environment and government intervention and
regulatory reform may lead to substantial new regulations and
disclosure obligations, which may lead to additional compliance
costs and impact the manner in which we operate our business in
ways we cannot currently anticipate.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We expect the rules and regulations applicable to public companies
to substantially increase our legal and financial compliance costs
and to make some activities more time-consuming and costly. If
these requirements divert the attention of our management and
personnel from other business concerns, they could have a material
adverse effect on our business, financial condition and results of
operations. The increased costs will decrease our net income or
increase our net loss, and may require us to reduce costs in other
areas of our business or increase the prices of our products or
services. For example, we expect these rules and regulations to
make it more difficult and more expensive for us to obtain director
and officer liability insurance and we may be required to incur
substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs
we may incur to respond to these requirements. The impact of these
requirements could also make it more difficult for us to attract
and retain qualified persons to serve on our board of directors,
our board committees or as executive officers.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
We may be exposed to risks relating to evaluations of controls
required by Sarbanes-Oxley Act of 2002.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Pursuant to Sarbanes-Oxley Act of 2002, our management will be
required to report on, and our independent registered public
accounting firm may in the future be required to attest to, the
effectiveness of our internal control over financial reporting.
Although we prepare our condensed financial statements in
accordance with accounting principles generally accepted in the
United States of America, our internal accounting controls may not
meet all standards applicable to companies with publicly traded
securities. If we fail to implement any required improvements to
our disclosure controls and procedures, we may be obligated to
report control deficiencies and our independent registered public
accounting firm may not be able to certify the effectiveness of our
internal controls over financial reporting. In either case, we
could become subject to regulatory sanction or investigation.
Further, these outcomes could damage investor confidence in the
accuracy and reliability of our condensed financial statements.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
46</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU47" id=
"_AEIOULastRenderedPageBreakAEIOU47"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure
to continue improving our accounting systems and controls could
impair our ability to comply with the financial reporting and
internal controls requirements for publicly traded
companies.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
As a public company, we operate in a demanding regulatory
environment, which requires us to comply with the Sarbanes-Oxley
Act of 2002, and the related rules and regulations of the SEC.
Company responsibilities required by the Sarbanes-Oxley Act include
establishing corporate oversight and adequate internal control over
financial reporting and disclosure controls and procedures.
Effective internal controls are necessary for us to produce
reliable financial reports and are important to help prevent
financial fraud.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We may need to retain additional finance capabilities and build our
financial infrastructure as a public company. Section 404(a) of the
Sarbanes-Oxley Act requires annual management assessments of the
effectiveness of our internal control over financial reporting,
starting with the second annual report that we would expect to file
with the SEC. However, for as long as we remain an “emerging growth
company” as defined in the JOBS Act, we have and intend to continue
to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are
not “emerging growth companies” including, but not limited to, not
being required to comply with the auditor attestation requirements
of Section 404(b) of the Sarbanes-Oxley Act. We may continue to
take advantage of these reporting exemptions until we are no longer
an “emerging growth company.” If we cannot provide reliable
financial reports or prevent fraud, our business and results of
operations could be harmed and investors could lose confidence in
our reported financial information.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Our ability to use our net operating loss carryforwards and certain
other tax attributes may be limited.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Under Sections 382 and 383 of the Internal Revenue Code of 1986, as
amended, or the Code, if a corporation undergoes an “ownership
change,” generally defined as a cumulative change in its equity
ownership by “5-percent shareholders” of greater than 50 percentage
points (by value) over a three-year period, the corporation’s
ability to use its pre-change net operating loss carryforwards, or
NOLs, and certain other pre-change tax attributes (such as research
tax credits) to offset its post-change taxable income and taxes, as
applicable, may be limited. We have completed multiple rounds of
financing since our inception which may have resulted in an
ownership change or could result in an ownership change in the
future. We have not completed a Section 382 and 383 analysis
regarding any limitations on our NOLs and research and development
credit carryforwards and such limitations could be significant. We
may also experience ownership changes in the future as a result of
subsequent shifts in our stock ownership. As a result, our ability
to use our NOLs and research and development credit carryforwards
to offset our U.S. federal taxable income and taxes, as applicable,
may be subject to limitations, which could potentially result in
increased future tax liability to us. In addition, at the state
level, similar rules may apply and there may be periods during
which the use of NOLs is suspended or otherwise limited, which
could accelerate or permanently increase state taxes owed.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Sales of a substantial number of shares of our common stock in the
public market could cause our stock price to fall.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
If our existing stockholders sell, or indicate an intention to
sell, substantial amounts of our common stock in the public market
after the lock-up and other legal restrictions on resale lapse, the
market price of our common stock could decline. There were
13,896,926 shares of common stock outstanding as of May 15, 2018.
Of these shares, 1,180,000 of the 1,280,000 shares sold in our
initial public offering are freely tradable, without restriction,
in the public market.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The remaining 12,716,926 shares offering are restricted as a result
of securities laws or lock-up agreements. The lock-up agreements
pertaining to our initial public offering will expire on September
24, 2018, 180 days from the date of the underwriting agreement
entered into in connection with our initial public offering.
Network 1 Financial Securities, Inc., the underwriter of our
initial public offering, may, however, in its sole discretion,
permit our officers, directors and other stockholders who are
subject to lock-up agreements to sell shares prior to the
expiration of the lock-up agreements.&nbsp;&nbsp;These remaining
shares will generally become available for sale in the public
market as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">up to 345,086 restricted
or control shares are eligible for sale, subject to compliance with
applicable securities laws; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">up to another 11,509,918
restricted shares will be eligible for sale upon the expiration of
lock-up agreements, also subject to compliance with applicable
securities laws.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, as of May 15, 2018, 7,575,209 shares of common stock
that are either subject to outstanding options, reserved for future
issuance under our equity incentive plan or subject to outstanding
warrants will become eligible for sale in the public market to the
extent permitted by the provisions of various vesting schedules,
the lock-up agreements and applicable securities laws. If these
additional shares of common stock are sold, or if it is perceived
that they will be sold, in the public market, the market price of
our common stock could decline.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
47</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU48" id=
"_AEIOULastRenderedPageBreakAEIOU48"></a><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future
sales and issuances of our common stock or rights to
purchas</font><font style=
"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e
common stock, including pursuant to our equity incentive plans,
could result in additional dilution of the percentage ownership of
our stockholders and could cause our stock price to
fall.</font></p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We intend to seek to raise additional funds, and we may finance
acquisitions or develop strategic relationships, in each case by
issuing equity or convertible debt securities in addition to the
shares issued in the recently completed initial public offering of
our common stock, which would reduce the percentage ownership of
our existing stockholders. Our board of directors has the
authority, in some instances without action or vote of the
stockholders, to issue our authorized but unissued shares of common
or preferred stock. Our amended and restated certificate of
incorporation authorizes us to issue up to 200,000,000 shares of
voting common stock and 10,000,000 shares of preferred stock.
Future issuances of common or preferred stock would reduce your
influence over matters on which stockholders vote and would be
dilutive to earnings per share. In addition, any newly issued
preferred stock could have rights, preferences and privileges
senior to those of the common stock. Those rights, preferences and
privileges could include, among other things, the establishment of
dividends that must be paid prior to declaring or paying dividends
or other distributions to holders of our common stock or providing
for preferential liquidation rights. These rights, preferences and
privileges could negatively affect the rights of holders of our
common stock, and the right to convert such preferred stock into
shares of our common stock at a rate or price that would have a
dilutive effect on the outstanding shares of our common stock.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Initially, the aggregate number of shares of our common stock that
may be issued pursuant to stock awards under our 2018 Plan is
6,788,749 shares. Additionally, the number of shares of our common
stock reserved for issuance under our 2018 Plan will automatically
increase on January 1 of each year, beginning on January 1, 2019
and continuing through and including January 1, 2028, by 5% of the
total number of shares of our capital stock outstanding on December
31 of the preceding calendar year, or a lesser number of shares
determined by our board of directors. Unless our board of directors
elects not to increase the number of shares available for future
grant each year, our stockholders may experience additional
dilution, which could cause our stock price to fall.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
If securities or industry analysts do not publish research or
reports about us, or if they adversely change their recommendations
regarding our common stock, then our stock price and trading volume
could decline.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The trading market for our common stock will be influenced by the
research and reports that industry or securities analysts publish
about us, our industry and our market. If no analyst elects to
cover us and publish research or reports about us, the market for
our common stock could be severely limited and our stock price
could be adversely affected. In addition, if one or more analysts
ceases coverage of us or fails to regularly publish reports on us,
we could lose visibility in the financial markets, which in turn
could cause our stock price or trading volume to decline. If one or
more analysts who elect to cover us issue negative reports or
adversely change their recommendations regarding our common stock,
our stock price could decline.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
The concentration of our common stock ownership by our current
management may limit your ability to influence corporate
matters.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our directors and executive officers beneficially own and are able
to vote in the aggregate approximately 22.0% of our outstanding
common stock. Accordingly, our directors and executive officers, as
stockholders, will continue to have the ability to exert
significant influence over all corporate activities, including the
election or removal of directors and the outcome of tender offers,
mergers, proxy contests or other purchases of common stock that
could give our stockholders the opportunity to realize a premium
over the then-prevailing market price for their shares of common
stock. This concentrated control will limit your ability to
influence corporate matters and, as a result, we may take actions
that purchasers in the recently completed initial public offering
of our common stock do not view as beneficial. In addition, such
concentrated control could discourage others from initiating
changes of control. In such cases, the perception of our prospects
in the market may be adversely affected and the market price of our
common stock may decline.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">
Certain provisions in our organizational documents could enable our
board of directors to prevent or delay a change of control.</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Our organizational documents contain provisions that may have the
effect of discouraging, delaying or preventing a change of control
of, or unsolicited acquisition proposals, that a stockholder might
consider favorable. These include provisions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">requiring a majority
vote of the outstanding shares of common stock to amend the
bylaws;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">provide that the
authorized number of directors may be changed only by resolution of
the board of directors;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">provide that the board
of directors or any individual director may only be removed with
cause and the affirmative vote of the holders of at least 66-2/3%
of the voting power of all of our then outstanding common
stock;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">provide that all
vacancies, including newly created directorships, may, except as
otherwise required by law, be filled by the affirmative vote of a
majority of directors then in office, even if less than a
quorum;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">divide our board of
directors into three classes;</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
48</p>
<hr style="page-break-after:always;width:100%;" />
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<a name="_AEIOULastRenderedPageBreakAEIOU49" id=
"_AEIOULastRenderedPageBreakAEIOU49"></a><font style=
"font-family:Times New Roman;">require that any action to be taken
by our stockholders must be effected at a duly called annual or
special meeting of stockholders and not be taken by written
consent;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">provide that
stockholders seeking to present proposals before a meeting of
stockholders or to nominate candidates for election as directors at
a meeting of stockholders must provide notice in writing in a
timely manner and also specify requirements as to the form and
content of a stockholder’s notice;</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">do not provide for
cumulative voting rights (therefore allowing the holders of a
majority of the shares of common stock entitled to vote in any
election of directors to elect all of the directors standing for
election, if they should so choose);</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">provide that special
meetings of our stockholders may be called only by the chairman of
the board, our Chief Executive Officer or by the board of directors
pursuant to a resolution adopted by a majority of the total number
of authorized directors; and</font></p>
</td>
</tr>
</table>
</div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
•</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">
<font style="font-family:Times New Roman;">provide that the Court
of Chancery of the State of Delaware will be the sole and exclusive
forum for (i) any derivative action or proceeding brought on our
behalf, (ii) any action asserting a claim of breach of a fiduciary
duty owed by any of our directors or officers to us or our
stockholders, (iii) any action asserting a claim against us arising
pursuant to any provision of the Delaware General Corporation Law
or our certificate of incorporation or bylaws, or (iv) any action
asserting a claim against us governed by the internal affairs
doctrine. This exclusive forum provision may limit a stockholder’s
ability to bring such an action in a judicial forum that it finds
favorable for such actions and may discourage such
actions.</font></p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Furthermore, our board of directors has the authority to issue
shares of preferred stock in one or more series and to fix the
rights and preferences of these shares without stockholder
approval. Any series of preferred stock is likely to be senior to
our common stock with respect to dividends, liquidation rights and,
possibly, voting rights. The ability of our board of directors to
issue preferred stock also could have the effect of discouraging
unsolicited acquisition proposals, thus adversely affecting the
market price of our common stock.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
In addition, Delaware law makes it difficult for stockholders that
recently have acquired a large interest in a corporation to cause
the merger or acquisition of the corporation against the directors’
wishes. Under Section 203 of the Delaware General Corporation Law,
a Delaware corporation may not engage in any merger or other
business combination with an interested stockholder for a period of
three years following the date that the stockholder became an
interested stockholder except in limited circumstances, including
by approval of the corporation’s board of directors.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="Item2.Unregistered" id="Item2.Unregistered"></a><a name=
"_bookmark11" id="_bookmark11"></a><a name=
"ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT" id=
"ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a><a name=
"ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT" id=
"ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a>Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Recent Sales of Unregistered Securities</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_cp_text_1_486" id="_cp_text_1_486"></a><a name=
"_Hlk511324146" id="_Hlk511324146"></a>During the three months
ended&nbsp;March 31, 2018, we issued and sold the following
unregistered securities&nbsp;(excluding those previously disclosed
in a Quarterly Report on Form 10-Q or in a Current Report on Form
8-K), in each case giving effect to the conversion of each share of
our outstanding preferred stock into one share of our common stock
and the 6.6841954-for-1 forward split of our common stock effected
in connection with the completion of our initial public offering in
April 2018:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style=
"border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.15%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(1)</font></p>
</td>
<td valign="top">
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">
On January 1, 2018, we issued 33,421 shares of our common stock to
a consultant in consideration of services provided by the
consultant.</p>
</td>
</tr>
</table>
</div>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The offer, sale and issuance of the securities described in
paragraph (1) was deemed to be exempt from registration under the
Securities Act in reliance on Section 4(2) (or Regulation D
promulgated thereunder) in that the issuance of securities to the
accredited investor did not involve a public offering. The
recipient of securities in this transaction acquired the securities
for investment only and not with a view to or for sale in
connection with any distribution thereof and appropriate legends
were affixed to the securities issued in these transactions. The
recipient of securities in this transaction was an accredited
investor under Rule 501 of Regulation D.</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The recipient of securities in this transaction had adequate
access, through employment, business or other relationships, to
information about us.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Use of Proceeds</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_cp_text_1_500" id="_cp_text_1_500"></a><a name=
"_cp_text_4_501" id="_cp_text_4_501"></a><a name="_cp_text_1_502"
id="_cp_text_1_502"></a><a name="_cp_text_4_503" id=
"_cp_text_4_503"></a><a name="_cp_text_1_504" id=
"_cp_text_1_504"></a><a name="_cp_text_4_505" id=
"_cp_text_4_505"></a><a name="_cp_text_1_506" id=
"_cp_text_1_506"></a><a name="_AEIOULastRenderedPageBreakAEIOU50"
id="_AEIOULastRenderedPageBreakAEIOU50"></a>On December 29,
2017,&nbsp;our Registration Statement on Form S-1, as amended (file
No. 333-219386) was declared effective by the SEC for our initial
public offering of common stock. We issued&nbsp;1,280,000 shares of
common stock at&nbsp;an offering price of $5.00 per share for gross
proceeds of $6.4 million.&nbsp;&nbsp;After deducting underwriting
discounts, commissions and offering costs incurred by us of $1.375
million, the net proceeds from the offering were $5.025
million.&nbsp;&nbsp;The offering was completed on April 3, 2018.
The lead</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
49</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
underwriter for the</font> <font style=
"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
offering was Network 1 Financial Securities, Inc. No offering costs
were paid or are payable, directly or indirectly, to our directors
or officers, to persons owning 10% or more of any class of our
equity securities, or to any of our affiliates.</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_cp_text_1_508" id="_cp_text_1_508"></a><a name=
"_Hlk511326375" id="_Hlk511326375"></a><a name="_cp_text_4_509" id=
"_cp_text_4_509"></a><a name="_cp_text_1_510" id=
"_cp_text_1_510"></a><a name="_cp_text_1_511" id=
"_cp_text_1_511"></a><a name="_cp_text_1_513" id=
"_cp_text_1_513"></a><a name="_cp_text_4_507" id=
"_cp_text_4_507"></a><a name="_cp_text_1_512" id=
"_cp_text_1_512"></a><a name="_cp_text_1_514" id=
"_cp_text_1_514"></a>We used approximately $200,000 of the net
proceeds of our initial public offering to repay a loan from Domecq
Sebastian, LLC, an owner of 10% or more of our common stock, as
discussed under “Certain Relationships and Related Transactions,
and Director Independence – Loan from Domecq Sebastian, LLC.”</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We used approximately $25,000 of the net proceeds of our initial
public offering to repay a loan from Viet Ly, an owner of 10% or
more of our common stock, as discussed under “Certain Relationships
and Related Transactions, and Director Independence – Loan from
Viet Ly.”</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
We used approximately $45,000 of the net proceeds of our initial
public offering to repay a loan from Rodney Varner, our Chief
Executive Officer and an owner of 10% or more of our common stock,
as discussed under “Certain Relationships and Related Transactions,
and Director Independence – Loan from Rodney Varner.”</p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
There has been no material change in the&nbsp;expected use of the
net proceeds from our initial public offering as described in the
final prospectus filed with the SEC on March 29, 2018 relating to
the recently completed initial public offering of our common stock.
Through May 15, 2018, we have used approximately $685,000 of the
net proceeds from the offering. Pending such uses, we plan to
continue investing the unused proceeds from the recently completed
initial public offering of our common stock in fixed,
non-speculative income instruments.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Purchases of Equity Securities by the Issuer and Affiliated
Purchasers</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_cp_text_1_516" id="_cp_text_1_516"></a>None.</p>
<p style=
"text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="Item6.Exhibits" id="Item6.Exhibits"></a><a name=
"_bookmark12" id="_bookmark12"></a><a name="ITEM_6_EXHIBITS" id=
"ITEM_6_EXHIBITS"></a><a name="ITEM_6_EXHIBITS" id=
"ITEM_6_EXHIBITS"></a>Item 6. Exhibits</p>
<p style=
"text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
The exhibits listed on the Index to Exhibits following the
signature page are filed as part of this Quarterly Report on Form
10-Q.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
50</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="_AEIOULastRenderedPageBreakAEIOU51" id=
"_AEIOULastRenderedPageBreakAEIOU51"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX
TO EXHIBITS</font></p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style=
"width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;color:#auto;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Exhibit</p>
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;color:#auto;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Number</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">
&nbsp;</p>
</td>
<td valign="bottom" style=
"padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:90%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;color:#auto;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
Description of Exhibit</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
31.1*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="gnpx-ex311_10.htm"><font style=
"text-decoration:underline;">Certification of Chief Executive
Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the
Securities Exchange Act of 1934, as adopted pursuant to Section 302
of the Sarbanes-Oxley Act of 2002.</font></a></p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
31.2*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="gnpx-ex312_9.htm"><font style=
"text-decoration:underline;">Certification of Chief Financial
Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the
Securities Exchange Act of 1934, as adopted pursuant to Section 302
of the Sarbanes-Oxley Act of 2002.</font></a></p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
32.1*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<a href="gnpx-ex321_8.htm"><font style=
"text-decoration:underline;">Certifications of Chief Executive
Officer and Chief Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.</font></a></p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
101.INS*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
XBRL Instance document.</p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
101.SCH*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
XBRL Taxonomy Extension Schema Document.</p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
101.CAL*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
XBRL Taxonomy Extension Calculation Linkbase Document.</p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
101.DEF*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
XBRL Taxonomy Extension Definition Linkbase Document</p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
101.LAB*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
XBRL Taxonomy Extension Label Linkbase Document</p>
</td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:9%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
<td colspan="2" valign="middle" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style="width:9%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
101.PRE*</p>
</td>
<td valign="bottom" style="width:1%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:90%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
XBRL Taxonomy Extension Presentation Document</p>
</td>
</tr>
</table>
</div>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
*Filed herewith.</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
51</p>
<hr style="page-break-after:always;width:100%;" />
<p style=
"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
<a name="SIGNATURES" id="SIGNATURES"></a><a name=
"_AEIOULastRenderedPageBreakAEIOU52" id=
"_AEIOULastRenderedPageBreakAEIOU52"></a><font style=
"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style=
"text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly
authorized.</p>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center"
style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td colspan="2" valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">
GENPREX, INC.</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:37%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style=
"width:60%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Date: May 15, 2018</p>
</td>
<td valign="top" style=
"width:3%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
By:</p>
</td>
<td valign="top" style=
"width:37%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
/s/ Rodney Varner</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="bottom" style="width:37%;white-space:nowrap;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Rodney Varner</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:37%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Chief Executive Officer</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:37%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(Principal Executive Officer)</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:37%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">
&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top" style=
"width:60%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style=
"width:3%; border-bottom:solid 0.75pt transparent;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
By:</p>
</td>
<td valign="top" style=
"width:37%; border-bottom:solid 0.75pt #000000;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
/s/ Ryan Confer</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:37%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Ryan Confer</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:37%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
Chief Financial Officer</p>
</td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">
&nbsp;</p>
</td>
<td valign="top" style="width:3%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
&nbsp;</p>
</td>
<td valign="top" style="width:37%;">
<p style=
"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
(Principal Financial Officer)</p>
</td>
</tr>
</table>
</div>
<p style=
"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">
&nbsp;</p>
<p style=
"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
52</p>
</body>
</html>

